

1: Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK, Kappos L, Labauge P, Miller A, Nakahara J, Oreja-Guevara C, Palace J, Singer B, Trojano M, Patil A, Rauser B, Hach T. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. *Neurol Neuroimmunol Neuroinflamm*. 2022 Nov 22;10(1):e200064. doi: 10.1212/NXI.0000000000200064. PMID: 36414428; PMCID: PMC9682625.

2: Falcicchio G, Negri F, Trojano M, La Neve A. On epilepsy perception: Unravelling gaps and issues. *Epilepsy Behav*. 2022 Dec;137(Pt A):108952. doi: 10.1016/j.yebeh.2022.108952. Epub 2022 Oct 25. PMID: 36306590.

3: Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand'Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H; Big MS Data Network. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. *J Neurol Neurosurg Psychiatry*. 2022 Sep 28:jnnp-2022-329987. doi: 10.1136/jnnp-2022-329987. Epub ahead of print. PMID: 36171104.

5: Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, Patti F, Pozzilli C, Preziosa P, Trojano M. Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. *J Neurol*. 2022 Dec;269(12):6690-6691. doi: 10.1007/s00415-022-11385-4. Erratum for: *J Neurol*. 2022 Oct;269(10):5382-5394. PMID: 36138162; PMCID: PMC9618484.

6: Schiavetti I, Carmisciano L, Ponzano M, Cordioli C, Cocco E, Marfia GA, Inglese M, Filippi M, Radaelli M, Bergamaschi R, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Trojano M, Lanzillo R, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 Study Group. Signs and symptoms of COVID-19 in patients with multiple sclerosis. *Eur J Neurol*. 2022 Dec;29(12):3728-3736. doi: 10.1111/ene.15554. Epub 2022 Sep 23. PMID: 36086905; PMCID: PMC9538224.

7: Brownlee WJ, Wolf C, Hartung HP, Dingerhans T, Anshasi N, Clark RA, Trojano M, Selmaj K, Uitdehaag BM, Tur C, Wuerfel J, Dallmann G, Witte J, Sintzel M, Bobrovnikova O, Cohen JA. Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. *Mult Scler*. 2022 Dec;28(14):2177-2189. doi: 10.1177/13524585221116269. Epub 2022 Aug 24. PMID: 36000489.

8: Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofri M, Brescia Morra V,

Zaffaroni M, Pozzilli C, Cocco E, Sola P, Salemi G, Inglese M, Bergamaschi R, Gasperini C, Conte A, Salvetti M, Lus G, Maniscalco GT, Totaro R, Vianello M, Granella F, Ferraro E, Aguglia U, Gatto M, Sangalli F, Chisari CG, De Luca G, Carotenuto A, Baroncini D, Colombo D, Nica M, Paolicelli D, Comi G, Filippi M, Amato MP, Trojano M. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. *Mult Scler*. 2022 Dec;28(14):2243-2252. doi: 10.1177/13524585221114007. Epub 2022 Aug 15. PMID: 35971322.

9: Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis. *JAMA Neurol*. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. PMID: 35877104; PMCID: PMC9315975.

10: Albano V, Dammacco R, Manni A, Sisto D, Iaffaldano A, Mavilio A, Alessio G, Trojano M, Paolicelli D. Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study. *Eur J Ophthalmol*. 2022 Jul 7:11206721221112803. doi: 10.1177/11206721221112803. Epub ahead of print. PMID: 35799453.

11: Baroncini D, Ghezzi A, Guaschino C, Moiola L, Filippi M, Ianniello A, Pozzilli C, Lanzillo R, Brescia-Morra V, Margoni M, Gallo P, Callari G, Grimaldi L, Lus G, Calabrese M, Simone M, Marfia GA, Rasia S, Cargnelutti D, Comi G, Zaffaroni M; MS Study Group of the Italian Neurological Society. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study. *Neurol Sci*. 2022 Nov;43(11):6415-6423. doi: 10.1007/s10072-022-06211-8. Epub 2022 Jul 4. PMID: 35781765.

12: Sorosina M, Barizzone N, Clarelli F, Anand S, Lupoli S, Salvi E, Mangano E, Bordoni R, Roostaei T, Mascia E, Zuccalà M, Vecchio D, Cavalla P, Santoro S, Ferrè L, Zollo A; PROGEMUS, Barlassina C, Cusi D, Martinelli V, Comi G, Leone M, Filippi M, Patsopoulos NA, De Jager PL, De Bellis G, Esposito F, D'Alfonso S, Martinelli Boneschi F. Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. *J Neurol*. 2022 Aug;269(8):4523-4524. doi: 10.1007/s00415-022-11216-6. Erratum for: *J Neurol*. 2022 Aug;269(8):4510-4522. PMID: 35751689; PMCID: PMC9293808.

13: La Neve A, Falcicchio G, Trojano M, Boero G. Seizure medication and planned pregnancy: balancing the risks and outcomes. *Expert Rev Neurother*. 2022 Jul;22(7):527-539. doi: 10.1080/14737175.2022.2093107. Epub 2022 Jun 27. PMID:

35726788.

14: Ponzano M, Schiavetti I, Bovis F, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Bragadin MM, Cocco E, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Bergamaschi R, Inglese M, Petracca M, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Karabudak R, Efendi H, Furlan R, Salvetti M, Sormani MP. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. *Mult Scler Relat Disord*. 2022 Jul;63:103909. doi: 10.1016/j.msard.2022.103909. Epub 2022 May 25. PMID: 35675744; PMCID: PMC9130313.

15: Trojano M, Kalincik T, Iaffaldano P, Amato MP. Interrogating large multiple sclerosis registries and databases: what information can be gained? *Curr Opin Neurol*. 2022 Jun 1;35(3):271-277. doi: 10.1097/WCO.0000000000001057. PMID: 35674068.

16: Bergamaschi R, Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Mosconi P; Italian Multiple Sclerosis and Related Disorders Register Centers Group and the Scientific Committee of Italian SM and Related Disorders Register, Aguglia U, Amato MP, Ancona AL, Ardito B, Avolio C, Balgera R, Banfi P, Barcella V, Barone P, Bellantonio P, Berardinelli A, Bergamaschi R, Bertora P, Bianchi M, Bramanti P, Morra VB, Brichetto G, Brioschi AM, Buccafusca M, Bucello S, Busillo V, Calchetti B, Cantello R, Capobianco M, Capone F, Capone L, Cargnelutti D, Carrozzini M, Cartechini E, Cavaletti G, Cavalla P, Celani MG, Clerici R, Clerico M, Cocco E, Confalonieri P, Coniglio MG, Conte A, Corea F, Cottone S, Crociani P, D'Andrea F, Danni MC, De Luca G, de Pascalis D, De Riz M, De Robertis F, De Rosa G, De Stefano N, Corte MD, Di Sapio A, Docimo R, Falcini M, Falcone N, Fermi S, Ferraro E, Ferrò MT, Fortunato M, Foschi M, Gajofatto A, Gallo A, Gallo P, Gatto M, Gazzola P, Giordano A, Granella F, Grasso MF, Grasso MG, Grimaldi LME, Iaffaldano P, Imperiale D, Inglese M, Iodice R, Leva S, Luezzi V, Lugaresi A, Lus G, Maimone D, Mancinelli L, Maniscalco GT, Marfia GA, Marini B, Marson A, Mascoli N, Massacesi L, Melani F, Merello M, Meucci G, Mirabella M, Montepietra S, Nasuelli D, Nicolao P, Passantino F, Patti F, Peresson M, Pesci I, Piantadosi C, Piras ML, Pizzorno M, Plewnia K, Pozzilli C, Protti A, Quatrone R, Realmuto S, Ribizzi G, Rinalduzzi S, Rini A, Romano S, Romeo M, Ronzoni M, Rossi P, Rovaris M, Salemi G, Santangelo G, Santangelo M, Santuccio G, Sarchielli P, Sinisi L, Sola P, Solaro C, Spitaleri D, Strumia S, Tassinari T, Tonietti S, Tortorella C, Totaro R, Tozzo A, Trivelli G, Ulivelli M, Valentino P, Venturi S, Vianello M, Zaffaroni M, Zarbo R, Trojano M, Battaglia MA, Capobianco M, Pugliatti M, Ulivelli M, Mosconi P, Gasperini C, Patti F, Amato MP, Bergamaschi R, Comi G. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. *Neurol Sci*. 2022 Sep;43(9):5459-5469. doi: 10.1007/s10072-022-06169-7. Epub 2022 Jun 7. PMID: 35672479; PMCID: PMC9385759.

17: Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G,

Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. *BMC Med Res Methodol.* 2022 May 30;22(1):155. doi: 10.1186/s12874-022-01623-8. PMID: 35637426; PMCID: PMC9150358.

18: Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, Patti F, Pozzilli C, Preziosa P, Trojano M. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. *J Neurol.* 2022 Oct;269(10):5382-5394. doi: 10.1007/s00415-022-11193-w. Epub 2022 May 24. Erratum in: *J Neurol.* 2022 Dec;269(12):6690-6691. PMID: 35608658; PMCID: PMC9489547.

19: Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, Alroughani R, Boz C, Shaygannejad V, van Pesch V, Cartechini E, Kappos L, Lechner-Scott J, Bergamaschi R, Turkoglu R, Solaro C, Iuliano G, Granella F, Van Wijmeersch B, Spitaleri D, Slee M, McCombe P, Prevost J, Ampapa R, Ozakbas S, Sanchez-Menoyo JL, Soysal A, Vucic S, Petersen T, de Gans K, Butler E, Hodgkinson S, Sidhom Y, Gouider R, Cristiano E, Castillo-Triviño T, Saladino ML, Barnett M, Moore F, Rozsa C, Yamout B, Skibina O, van der Walt A, Buzzard K, Gray O, Hughes S, Sempere AP, Singhal B, Fragoso Y, Shaw C, Kermode A, Taylor B, Simo M, Shuey N, Al-Harbi T, Macdonell R, Dominguez JA, Csepany T, Sirbu CA, Sormani MP, Butzkueven H, Kalincik T. Confirmed disability progression as a marker of permanent disability in multiple sclerosis. *Eur J Neurol.* 2022 Aug;29(8):2321-2334. doi: 10.1111/ene.15406. Epub 2022 Jun 9. PMID: 35582938; PMCID: PMC9539581.

20: Sorosina M, Barizzone N, Clarelli F, Anand S, Lupoli S, Salvi E, Mangano E, Bordoni R, Roostaei T, Mascia E, Zuccalà M, Vecchio D, Cavalla P, Santoro S, Ferrè L, Zollo A; PROGEMUS, Barlassina C, Cusi D, Martinelli V, Comi G, Leone M, Filippi M, Patsopoulos NA, De Jager PL, De Bellis G, Esposito F, D'Alfonso S, Martinelli Boneschi F. A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. *J Neurol.* 2022

Aug;269(8):4510-4522. doi: 10.1007/s00415-022-11109-8. Epub 2022 May 12. Erratum in: *J Neurol*. 2022 Jun 25;: PMID: 35545683; PMCID: PMC9294010.

21: Bollo L, Caputo F, Paolicelli D, Trojano M, Iaffaldano P. Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate. *Intern Emerg Med*. 2022 Sep;17(6):1845-1847. doi: 10.1007/s11739-022-02989-9. Epub 2022 Apr 29. PMID: 35486330; PMCID: PMC9051806.

22: Portaccio E, Bellinvia A, Razzolini L, Pastò L, Goretti B, Niccolai C, Fonderico M, Zaffaroni M, Pippolo L, Moiola L, Falautano M, Celico C, Viterbo R, Patti F, Chisari C, Gallo P, Riccardi A, Borghi M, Bertolotto A, Simone M, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Filippi M, Trojano M, Ghezzi A, Amato MP; MS Study Group of the Italian Neurological Society. Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. *Neurology*. 2022 Apr 19;98(16):e1626-e1636. doi: 10.1212/WNL.0000000000200115. PMID: 35437271.

23: Amato MP, De Stefano N, Inglese M, Morena E, Ristori G, Salvetti M, Trojano M. Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis. *Front Neurol*. 2022 Mar 14;13:787160. doi: 10.3389/fneur.2022.787160. PMID: 35359637; PMCID: PMC8964010.

24: Portaccio E, Bellinvia A, Fonderico M, Pastò L, Razzolini L, Totaro R, Spitaleri D, Lugaresi A, Cocco E, Onofri M, Di Palma F, Patti F, Maimone D, Valentino P, Confalonieri P, Protti A, Sola P, Lus G, Maniscalco GT, Brescia Morra V, Salemi G, Granella F, Pesci I, Bergamaschi R, Aguglia U, Vianello M, Simone M, Lepore V, Iaffaldano P, Filippi M, Trojano M, Amato MP. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. *Brain*. 2022 Aug 27;145(8):2796-2805. doi: 10.1093/brain/awac111. PMID: 35325059.

25: Portaccio E, Pastò L, Razzolini L, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Gasperini C, Paolicelli D, Simone M, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Comi G, Filippi M, Trojano M, Amato MP. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. *Mult Scler*. 2022 Nov;28(13):2137-2141. doi: 10.1177/13524585221079598. Epub 2022 Mar 16. PMID: 35296189.

26: Bollo L, Santoro C, Libro G, Pellicciari R, Paolicelli D, Iaffaldano P, Trojano M. Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review. *Neurol Sci*. 2022 Jun;43(6):4015-4018. doi: 10.1007/s10072-022-05984-2. Epub 2022 Mar 15. PMID: 35288788.

29: Butzkueven H, Giacomini PS, Cohan S, Ziemssen T, Sienkiewicz D, Zhang Y, Geissbühler Y, Silva D, Tomic D, Kropshofer H, Trojano M. Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study. *Brain Sci.* 2022 Feb 4;12(2):215. doi: 10.3390/brainsci12020215. PMID: 35203978; PMCID: PMC8870332.

30: Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinschenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. *April 2021. Mult Scler.* 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23. PMID: 35196927.

31: Valente O, Messina R, Ingravallo G, Bellitti E, Zimatore DS, de Gennaro L, Abbrescia P, Pati R, Palazzo C, Nicchia GP, Trojano M, Signorelli F, Frigeri A. Alteration of the translational readthrough isoform AQP4ex induces redistribution and downregulation of AQP4 in human glioblastoma. *Cell Mol Life Sci.* 2022 Feb 20;79(3):140. doi: 10.1007/s00018-021-04123-y. PMID: 35187599; PMCID: PMC8858924.

32: De Meo E, Filippi M, Trojano M, Comi G, Patti F, Brescia Morra V, Salemi G, Onofri M, Lus G, Cocco E, Fonderico M, Torri Clerici V, Maniscalco GT, Valentino P, Bertolotto A, Lugaresi A, Bergamaschi R, Rovaris M, Sola P, Tedeschi G, Pesci I, Aguglia U, Cavalla P, Maimone D, Granella F, Vianello M, Simone M, Portaccio E, Amato MP. Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis. *Ann Neurol.* 2022 Apr;91(4):483-495. doi: 10.1002/ana.26322. Epub 2022 Feb 28. PMID: 35150168.

33: Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M; Italian MS Register. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study. *Neurol Neuroimmunol Neuroinflamm.* 2022 Jan 19;9(2):e1141. doi: 10.1212/NXI.0000000000001141. PMID: 35046084; PMCID: PMC8771668.

34: Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, Amico E;

Italian MS register. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. *Mult Scler Relat Disord*. 2022 Feb;58:103489. doi: 10.1016/j.msard.2022.103489. Epub 2022 Jan 2. PMID: 35032879.

35: Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H; MSBase Investigators. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. *Pharmacoeconomics*. 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18. PMID: 34921350; PMCID: PMC8866337.

36: Pilotto S, Gencarelli J, Bova S, Gerosa L, Baroncini D, Olivetto S, Alfei E, Zaffaroni M, Suppiej A, Cocco E, Trojano M, Amato MP, D'Alfonso S, Martinelli-Boneschi F, Waubant E, Ghezzi A, Bergamaschi R, Pugliatti M. Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDIatric Italian Genetic and enviRonment ExposurE Questionnaire). *Mult Scler J Exp Transl Clin*. 2021 Dec 1;7(4):20552173211059048. doi: 10.1177/20552173211059048. PMID: 34868629; PMCID: PMC8640303.

37: Lia A, Annese T, Fornaro M, Giannini M, D'Abbicco D, Errede M, Lorusso L, Amati A, Tampoia M, Trojano M, Virgintino D, Ribatti D, Serlenga L, Iannone F, Girolamo F. Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy. *Rheumatology (Oxford)*. 2022 Aug 3;61(8):3448-3460. doi: 10.1093/rheumatology/keab900. PMID: 34864921.

38: Alicino AM, Falcicchio G, Boero G, Santarcangelo G, Francavilla T, Trojano M, La Neve A. Perampanel during pregnancy: Description of four cases. *Epilepsy Behav Rep*. 2021 Oct 8;16:100490. doi: 10.1016/j.ebr.2021.100490. PMID: 34761195; PMCID: PMC8567359.

39: Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Bricchetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; MuSC-19 Study Group. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. *Neurol Neuroimmunol Neuroinflamm*. 2021 Nov 9;9(1):e1105. doi: 10.1212/NXI.0000000000001105. PMID: 34753829; PMCID: PMC8579249.

40: De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrij M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott

J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepány T, Ramo-Tello C, Peeters L. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: *Comput Methods Programs Biomed.* 2022 Jan;213:106479. doi: 10.1016/j.cmpb.2021.106479. Epub 2021 Nov 5. Erratum for: *Comput Methods Programs Biomed.* 2021 Sep;208:106180. PMID: 34749246.

41: Bergamaschi R, Ponzano M, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Bricchetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Pisoni E, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 study group. The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. *Eur J Neurol.* 2022 Feb;29(2):535-542. doi: 10.1111/ene.15167. Epub 2021 Nov 15. PMID: 34735749; PMCID: PMC8652772.

42: Santoro C, Guerra T, D'Errico E, Fraddosio A, Lapenna F, Introna A, Trojano M. Guillain-Barré syndrome associated with inappropriate secretion of antidiuretic hormone following SARS-CoV-2 infection: A case-report. *Clin Case Rep.* 2021 Oct 18;9(10):e04667. doi: 10.1002/ccr3.4667. PMID: 34703597; PMCID: PMC8521282.

43: Filippi M, Danesi R, Derfuss T, Duddy M, Gallo P, Gold R, Havrdová EK, Kornek B, Saccà F, Tintoré M, Weber J, Trojano M. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. *J Neurol.* 2022 Mar;269(3):1670-1677. doi: 10.1007/s00415-021-10836-8. Epub 2021 Oct 9. PMID: 34626224; PMCID: PMC8501364.

44: Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. *J Med Internet Res.* 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. PMID: 34612826; PMCID: PMC8529467.

45: Butzkueven H, Kappos L, Spelman T, Trojano M, Wiendl H, Su R, Liao S, Hyde R, Licata S, Ho PR, Campbell N. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). *Ther Adv Neurol Disord.* 2021 Sep 27;14:17562864211042458. doi: 10.1177/17562864211042458. PMID: 34603507; PMCID: PMC8481711.

46: Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK,

Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofri M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepány T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzl O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pflieger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. *CNS Drugs*. 2021 Nov;35(11):1217-1232. doi: 10.1007/s40263-021-00860-7. Epub 2021 Sep 18. PMID: 34536228.

47: Guerra T, Bollo L, Trojano M, Iaffaldano P. Dengue fever in a multiple sclerosis patient taking Ocrelizumab. *Mult Scler*. 2021 Nov;27(13):2116-2118. doi: 10.1177/13524585211030214. Epub 2021 Aug 27. PMID: 34449289.

48: Intron A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, Trojano M. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? *Clin Neurol Neurosurg*. 2021 Sep;208:106887. doi: 10.1016/j.clineuro.2021.106887. Epub 2021 Aug 13. PMID: 34418708; PMCID: PMC8360997.

49: Negri L, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Gasperini C, Minacapelli E, Patti F, Trojano M, Bassi M. Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. *Neurol Sci*. 2022 Mar;43(3):1903-1910. doi: 10.1007/s10072-021-05520-8. Epub 2021 Aug 7. PMID: 34363548; PMCID: PMC8346783.

50: Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. *Mult Scler*. 2022 Jun;28(7):1034-1040. doi: 10.1177/13524585211035318. Epub 2021 Jul 30. PMID: 34328824.

51: Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, Zaffaroni M, Mirabella M, Lus G, Patti F, Cavalla P, Cellerino M, Malucchi S, Pisano E, Vitetta F, Paolicelli D, Sola P, Trojano M; Italian MS Register. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting

agents: the role of washout duration. *J Neurol*. 2022 Mar;269(3):1463-1469. doi: 10.1007/s00415-021-10708-1. Epub 2021 Jul 22. PMID: 34292396.

52: Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. *Ann Clin Transl Neurol*. 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. Epub 2021 Jul 7. PMID: 34240579; PMCID: PMC8351392.

53: Zanghì A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, D'Amico E; Italian MS register. First-line therapies in late-onset multiple sclerosis: An Italian registry study. *Eur J Neurol*. 2021 Dec;28(12):4117-4123. doi: 10.1111/ene.15006. Epub 2021 Jul 30. PMID: 34216532; PMCID: PMC9291454.

54: De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, José Sá M, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. *Comput Methods Programs Biomed*. 2021 Sep;208:106180. doi: 10.1016/j.cmpb.2021.106180. Epub 2021 May 18. Erratum in: *Comput Methods Programs Biomed*. 2022 Jan;213:106479. PMID: 34146771.

55: Portaccio E, Tudisco L, Pastò L, Razzolini L, Fonderico M, Bellinvia A, Ghezzi A, Annovazzi P, Zaffaroni M, Moiola L, Martinelli V, Chisari CG, Patti F, Mancardi G, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Cocco E, Marrosu MG, Comi G, Filippi M, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. *Mult Scler*. 2022 Mar;28(3):472-479. doi: 10.1177/13524585211023365. Epub 2021 Jun 16. PMID: 34132146.

56: Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou

P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Leray E, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. *Mult Scler Relat Disord*. 2021 Aug;53:103012. doi: 10.1016/j.msard.2021.103012. Epub 2021 May 8. PMID: 34116480.

57: Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Brescia Morra V, Pozzilli C, De Luca G, Inglese M, Salemi G, Maniscalco GT, Cocco E, Sola P, Lus G, Conte A, Amato MP, Granella F, Gasperini C, Bellantonio P, Totaro R, Rovaris M, Salvetti M, Torri Clerici VLA, Bergamaschi R, Maimone D, Scarpini E, Capobianco M, Comi G, Filippi M, Trojano M; Italian MS Register. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. *Ther Adv Neurol Disord*. 2021 May 31;14:17562864211019574. doi: 10.1177/17562864211019574. PMID: 34104220; PMCID: PMC8170278.

58: Centonze D, Fantozzi R, Buttari F, Grimaldi LME, Totaro R, Corea F, Marrosu MG, Confalonieri P, Cottone S, Trojano M, Zipoli V. Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). *Front Neurol*. 2021 Apr 22;12:637615. doi: 10.3389/fneur.2021.637615. PMID: 33967938; PMCID: PMC8101263.

59: Gentile E, Delussi M, Abagnale C, Caponnetto V, De Cesaris F, Frattale I, Guaschino E, Marcinnò A, Ornello R, Pistoia F, Putortì A, Candida G, Roveta F, Lupi C, Coppola G, Prudenzeno AMP, Rainero I, Sances G, Roca ME, Trojano M, Pierelli F, Geppetti P, Sacco S, de Tommaso M. Migraine during COVID-19: Data from Second Wave Pandemic in an Italian Cohort. *Brain Sci*. 2021 Apr 10;11(4):482. doi: 10.3390/brainsci11040482. PMID: 33920175; PMCID: PMC8070557.

60: Paolicelli D, Manni A, Iaffaldano A, Tancredi G, Ricci K, Gentile E, Viterbo RG, Quitadamo SG, de Tommaso M, Trojano M. Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue. *Brain Sci*. 2021 Apr 9;11(4):481. doi: 10.3390/brainsci11040481. PMID: 33918861; PMCID: PMC8069556.

61: Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. *Mult Scler*. 2021 Sep;27(10):1543-1555. doi: 10.1177/13524585211010128. Epub 2021 Apr 26. PMID: 33900144.

62: Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung HP, Magyari M, Oreja-Guevara C, Trojano M, Wiendl H, Filippi M. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. *J Neurol*. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12. PMID: 33844056; PMCID: PMC8038920.

63: Trojano M, Ramió-Torrentà L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, Ren Z, Muralidharan KK, Licata S, Gafson AR. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. *Mult Scler*. 2021 Dec;27(14):2240-2253. doi: 10.1177/13524585211003020. Epub 2021 Apr 6. PMID: 33821693; PMCID: PMC8597184.

64: Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T. Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. *Front Neurol*. 2021 Mar 17;12:647811. doi: 10.3389/fneur.2021.647811. PMID: 33815259; PMCID: PMC8010264.

65: Bollo L, Iaffaldano P, Ruggieri M, Palazzo C, Mastrapasqua M, Manni A, Paolicelli D, Frigeri A, Trojano M. Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMO/MS by a Semiquantitative Ratiometric Method. *Front Neurol*. 2021 Mar 8;12:633115. doi: 10.3389/fneur.2021.633115. PMID: 33763015; PMCID: PMC7982799.

66: Wang EW, Trojano ML, Lewis MM, Du G, Chen H, Brown GL, Jellen LC, Song I, Neely E, Kong L, Connor JR, Huang X. HFE H63D Limits Nigral Vulnerability to Paraquat in Agricultural Workers. *Toxicol Sci*. 2021 Apr 27;181(1):47-57. doi: 10.1093/toxsci/kfab020. PMID: 33739421; PMCID: PMC8081021.

67: Guerra T, Caputo F, Orlando B, Paolicelli D, Trojano M, Iaffaldano P. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years. *Neurol Sci*. 2021 Nov;42(11):4647-4655. doi: 10.1007/s10072-021-05127-z. Epub 2021 Mar 6. PMID: 33677753; PMCID: PMC8519830.

68: Trojano M, Iaffaldano P. Assessing long-term effectiveness of MS treatment - a matter of debate. *Nat Rev Neurol*. 2021 Apr;17(4):197-198. doi: 10.1038/s41582-021-00476-x. PMID: 33633380.

69: Filippi M, Capra R, Centonze D, Gasperini C, Patti F, Perini P, Pozzilli C, Rocca MA, Uccelli A, Trojano M. Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. *J Neurol*. 2021 Apr;268(4):1540-1543. doi: 10.1007/s00415-021-10466-0. Epub 2021 Feb 20. PMID: 33609155; PMCID: PMC7896178.

70: D'Amico E, Zanghì A, Romeo M, Cocco E, Maniscalco GT, Brescia Morra V, Paolicelli D, De Luca G, Galgani S, Amato MP, Salemi G, Inglese M, Confalonieri PA, Lus G, Avolio C, Gallo A, Vianello M, Onofri M, Filippi M, Trojano M, Patti F. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. *Neurotherapeutics*. 2021 Apr;18(2):905-919. doi: 10.1007/s13311-020-01001-6. Epub 2021 Feb 2. PMID: 33528815; PMCID: PMC8423935.

71: Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Muiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Ann Neurol*. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9. PMID: 33480077; PMCID: PMC8013440.

72: Roos I, Leray E, Frascoli F, Casey R, Brown JW, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofri M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand'Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepány T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T. Determinants of therapeutic lag in multiple sclerosis. *Mult Scler*. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300. Epub 2021 Jan 11. PMID: 33423618.

73: Signorile A, Ferretta A, Ruggieri M, Paolicelli D, Lattanzio P, Trojano M, De Rasmio D. Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceuticals. *Antioxidants (Basel)*. 2020 Dec 28;10(1):21. doi: 10.3390/antiox10010021. PMID: 33379309; PMCID: PMC7823468.

74: Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand'Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermodé A, Csepány T, Singhal B, Shuey N, Piroška I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study Group. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. *Neurology*. 2021 Feb 2;96(5):e783-e797. doi:

10.1212/WNL.0000000000011242. Epub 2020 Dec 28. PMID: 33372028; PMCID: PMC7884998.

75: Parisi M, Manni A, Caputo F, Trojano M, Paolicelli D. A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. *Brain Behav.* 2021 Jan;11(1):e01930. doi: 10.1002/brb3.1930. Epub 2020 Dec 16. PMID: 33325640; PMCID: PMC7821561.

76: Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, Durelli L, Marignier R, Gignoux L, Laplaud DA, Moreau T, Clavelou P, De Seze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Trojano M, Patti F, Baulieu EE, Remontet L, El-Etr M. Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. *Mult Scler.* 2021 Aug;27(9):1458-1463. doi: 10.1177/1352458520978218. Epub 2020 Dec 3. PMID: 33269975.

77: Delussi M, Gentile E, Coppola G, Prudenzano AMP, Rainero I, Sances G, Abagnale C, Caponnetto V, De Cesaris F, Frattale I, Guaschino E, Marcinnò A, Ornello R, Pistoia F, Putortì A, Roca ME, Roveta F, Lupi C, Trojano M, Pierelli F, Geppetti P, Sacco S, de Tommaso M. Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RiCe). *Front Neurol.* 2020 Nov 10;11:597881. doi: 10.3389/fneur.2020.597881. PMID: 33240213; PMCID: PMC7683429.

78: Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaesi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi G, Filippi M, Amato MP, Trojano M; Italian MS Register. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. *Mult Scler.* 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366. Epub 2020 Nov 19. PMID: 33210986.

79: Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *Eur J Neurol.* 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6. PMID: 33058344.

80: Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S, Sparaco M, Rovaris M, D'Arma A, Lugaesi A, Ferrò MT, Grossi P, Di Sapio A, Cocco E, Granella F, Curti E, Lepore V, Trojano M, Patti F; Italian MS Register Study Group. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2020 Dec;91(12):1297-1303. doi:

10.1136/jnnp-2020-323472. Epub 2020 Oct 14. PMID: 33055141.

81: Bovis F, Kalincik T, Lublin F, Cutter G, Malpas C, Horakova D, Havrdova EK, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Izquierdo G, Eichau S, Patti F, Terzi M, Grammond P, Bergamaschi R, Sola P, Ferraro D, Ozakbas S, Iuliano G, Boz C, Hupperts R, Grand'Maison F, Oreja-Guevara C, van Pesch V, Cartechini E, Petersen T, Altintas A, Soysal A, Ramo-Tello C, McCombe P, Turkoglu R, Butzkueven H, Wolinsky JS, Solaro C, Sormani MP. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. *Neurology*. 2021 Jan 12;96(2):e214-e227. doi: 10.1212/WNL.0000000000010991. Epub 2020 Oct 6. PMID: 33024022; PMCID: PMC7905777.

82: Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. *Brain*. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231. PMID: 32947619.

83: Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. *Brain*. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251. PMID: 32935843.

84: Ruggieri M, Gargano CD, Ferretta A, Manni A, Capacchione A, Frigeri A, Iaffaldano P, Trojano M, Paolicelli D. Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy. *Brain Sci*. 2020 Aug 13;10(8):548. doi: 10.3390/brainsci10080548. PMID: 32823496; PMCID: PMC7464206.

85: Lizak N, Malpas CB, Sharmin S, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Lugaresi A, Duquette P, Girard M, Prat A, Larochelle C, Trojano M, Grand'Maison F, Grammond P, Sola P, Ferraro D, Hupperts R, Bergamaschi R, Boz C, Van Pesch V, Spitaleri D, Terzi M, Kalincik T; MSBase Study Group. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. *JAMA Neurol*. 2020 Nov 1;77(11):1398-1407. doi: 10.1001/jamaneurol.2020.2453. Erratum in: *JAMA Neurol*. 2021 Jan 1;78(1):120. PMID: 32716480; PMCID: PMC7385679.

86: Caputo F, Manni A, Iaffaldano P, Trojano M, Paolicelli D. Durvalumab and multiple sclerosis: a causal link or simple unmasking? *Eur J Clin Pharmacol*. 2020 Dec;76(12):1773-1774. doi: 10.1007/s00228-020-02959-0. Epub 2020 Jul 13. PMID: 32661572.

87: Bollo L, Guerra T, Bavaro DF, Monno L, Saracino A, Angarano G, Paolicelli D, Trojano M, Iaffaldano P. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. *J Neurol Sci*. 2020 Sep 15;416:117011. doi: 10.1016/j.jns.2020.117011. Epub 2020 Jul 4. PMID: 32650143; PMCID: PMC7339938.

88: Kunchok A, Lechner-Scott J, Granella F, Trojano M, Alroughani R, Sola P, Ferraro D, Lugaresi A, Onofri M, Ozakbas S, Izquierdo G, Grammond P, Luis Sanchez-Menoyo J, Van Wijmeersch B, Boz C, Pucci E, McCombe P, Grand'Maison F, Spitaleri D, Vucic S, Hupperts R, Jokubaitis V, Sormani MP, Butzkueven H, Kalincik T; MSBase Study Group. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. *Mult Scler*. 2021 Apr;27(5):695-705. doi: 10.1177/1352458520936823. Epub 2020 Jul 8. PMID: 32639855.

89: Patti F, Visconti A, Capacchione A, Roy S, Trojano M; CLARINET-MS Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). *Ther Adv Neurol Disord*. 2020 Jun 10;13:1756286420922685. doi: 10.1177/1756286420922685. PMID: 32587633; PMCID: PMC7294475.

90: Wiendl H, Spelman T, Butzkueven H, Kappos L, Trojano M, Su R, Campbell N, Ho PR, Licata S. Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. *Mult Scler*. 2021 Apr;27(5):719-728. doi: 10.1177/1352458520926869. Epub 2020 Jun 24. PMID: 32579430.

91: Ghezzi A, Amato MP, Edan G, Hartung HP, Havrdová EK, Kappos L, Montalban X, Pozzilli C, Sorensen PS, Trojano M, Vermersch P, Comi G. The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. *Mult Scler*. 2021 Mar;27(3):479-482. doi: 10.1177/1352458520930620. Epub 2020 Jun 16. PMID: 32539596.

92: Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Laroche C, Alroughani R, Bergamaschi R, Sola P, Ferraro D, Grammond P, Grand' Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. *Mult Scler*. 2021 Apr;27(5):755-766. doi: 10.1177/1352458520926955. Epub 2020 Jun 15. PMID: 32538713.

93: Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L; 2018ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. *Mult Scler*. 2020 Jun 12;26(9):1352458520925369. doi: 10.1177/1352458520925369. Epub ahead of print. PMID: 32530385; PMCID: PMC7412876.

94: Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M; 2018ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (2): Treatment. *Mult Scler*. 2020 Jun 12;26(9):1352458520924595. doi: 10.1177/1352458520924595. Epub ahead of print. PMID: 32530366; PMCID: PMC7412878.

95: Butzkueven H, Trojano M, Kappos L, Spelman T, Wiendl H, Rosales K, Su R, Licata S, Ho PR, Campbell N. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri[®] Observational Program (TOP). *Mult Scler*. 2021 Mar;27(3):410-419. doi: 10.1177/1352458520917925. Epub 2020 May 14. PMID: 32406786.

96: Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Eichau S, Bergamaschi R, Sola P, Ferraro D, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Grand'Maison F, Ozakbas S, Van Pesch V, Granella F, Hupperts R, Pucci E, Boz C, Sidhom Y, Gouider R, Spitaleri D, Soysal A, Petersen T, Verheul F, Karabudak R, Turkoglu R, Ramo-Tello C, Terzi M, Cristiano E, Slee M, McCombe P, Macdonell R, Fragoso Y, Olascoaga J, Altintas A, Olsson T, Butzkueven H, Hillert J, Kalincik T. Early clinical markers of aggressive multiple sclerosis. *Brain*. 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081. PMID: 32386427.

97: Amato MP, Goretti B, Brescia Morra V, Gallo P, Zaffaroni M, Onofri M, Cocco E, Borriello G, Zipoli V, Trojano M. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. *Neurol Sci*. 2020 Nov;41(11):3185-3193. doi: 10.1007/s10072-020-04320-w. Epub 2020 May 1. PMID: 32358701.

98: Comi G, Pozzilli C, Morra VB, Bertolotto A, Sangalli F, Prosperini L, Carotenuto A, Iaffaldano P, Capobianco M, Colombo D, Nica M, Rizzoli S, Trojano M. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. *Neurol Sci*. 2020 Oct;41(10):2843-2851. doi: 10.1007/s10072-020-04380-y. Epub 2020 Apr 21. PMID: 32318950; PMCID: PMC7479005.

99: De Rasmio D, Ferretta A, Russo S, Ruggieri M, Lasorella P, Paolicelli D, Trojano M, Signorile A. PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels. *Biomedicines*. 2020 Apr 11;8(4):85. doi: 10.3390/biomedicines8040085. PMID: 32290388; PMCID: PMC7235786.

100: Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). *J Neurol Neurosurg Psychiatry*. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. PMID: 32234967; PMCID: PMC7279201.

101: He A, Merkel B, Brown JW, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T; MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol*. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. PMID: 32199096.

102: Mantovani LG, Cozzolino P, Cortesi PA, Patti F; SA.FE. study group. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. *Clin Drug Investig*. 2020 Apr;40(4):319-326. doi: 10.1007/s40261-020-00895-6. PMID: 32130684.

103: Palazzo C, Abbrescia P, Valente O, Nicchia GP, Banitalebi S, Amiry-Moghaddam M, Trojano M, Frigeri A. Tissue Distribution of the Readthrough Isoform of AQP4 Reveals a Dual Role of AQP4ex Limited to CNS. *Int J Mol Sci*. 2020 Feb 24;21(4):1531. doi: 10.3390/ijms21041531. PMID: 32102323; PMCID: PMC7073200.

104: Negri L, Minacapelli E, Bassi M, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Gasperini C, Patti F, Trojano M, Delle Fave A. Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). *Neurol Sci*. 2020 Jul;41(7):1881-1889. doi: 10.1007/s10072-020-04302-y. Epub 2020 Feb 24. PMID: 32095946.

105: Mallucci G, Patti F, Brescia Morra V, Buccafusca M, Moiola L, Amato MP, Ferraro E, Trojano M, Zaffaroni M, Mirabella M, Moscato G, Plewnia K, Zipoli V, Puma E, Bergamaschi R; BREMSO-group. A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β 1a in multiple sclerosis patients. *Mult Scler Relat Disord*. 2020 May;40:101952. doi: 10.1016/j.msard.2020.101952. Epub 2020 Jan 21. PMID: 32007656.

106: Antonucci LA, Pergola G, Pignoni A, Dwyer D, Kambeitz-Illankovic L, Penzel N, Romano R, Gelao B, Torretta S, Rampino A, Trojano M, Caforio G, Falkai P, Blasi G, Koutsouleris N, Bertolino A. A Pattern of Cognitive Deficits Stratified for

Genetic and Environmental Risk Reliably Classifies Patients With Schizophrenia From Healthy Control Subjects. *Biol Psychiatry*. 2020 Apr 15;87(8):697-707. doi: 10.1016/j.biopsych.2019.11.007. Epub 2019 Nov 15. PMID: 31948640.

107: Paolicelli D, Manni A, Iaffaldano A, Trojano M. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. *CNS Drugs*. 2020 Jan;34(1):65-92. doi: 10.1007/s40263-019-00691-7. PMID: 31898276.

108: Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrij M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. *Mult Scler Relat Disord*. 2020 Feb;38:101868. doi: 10.1016/j.msard.2019.101868. Epub 2019 Nov 25. PMID: 31877445.

109: Bassi M, Grobberio M, Negri L, Cilia S, Minacapelli E, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Falautano M, Gasperini C, Patti F, Trojano M, Delle Fave A. The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. *J Clin Psychol Med Settings*. 2021 Mar;28(1):149-160. doi: 10.1007/s10880-019-09692-6. PMID: 31872372.

110: Cohen JA, Trojano M, Mowry EM, Uitdehaag BM, Reingold SC, Marrie RA. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. *Mult Scler*. 2020 Jan;26(1):23-37. doi: 10.1177/1352458519892555. Epub 2019 Nov 28. PMID: 31778094; PMCID: PMC6950891.

111: Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S; Italian Consensus Group on treatment of spasticity in multiple sclerosis. Italian consensus on treatment of spasticity in multiple sclerosis. *Eur J Neurol*. 2020 Mar;27(3):445-453. doi: 10.1111/ene.14110. Epub 2019 Dec 3. PMID: 31652369.

112: Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. *J Neurol*. 2019 Dec;266(12):3098-3107. doi: 10.1007/s00415-019-09531-6. Epub 2019

Sep 18. PMID: 31535270.

113: Bassi M, Cilia S, Falautano M, Grobberio M, Negri L, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Gasperini C, Minacapelli E, Patti F, Trojano M, Delle Fave A. The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. *Health Soc Care Community*. 2020 Jan;28(1):236-246. doi: 10.1111/hsc.12858. Epub 2019 Sep 16. PMID: 31524966.

114: Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Risk of secondary progressive multiple sclerosis: A longitudinal study. *Mult Scler*. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9. PMID: 31397221.

115: Manni A, Iaffaldano A, Lucisano G, D'Onghia M, Mezzapesa DM, Felica V, Iaffaldano P, Trojano M, Paolicelli D. Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort. *Front Immunol*. 2019 Jun 14;10:1343. doi: 10.3389/fimmu.2019.01343. PMID: 31258529; PMCID: PMC6587065.

116: Girolamo F, Lia A, Annese T, Giannini M, Amati A, D'Abbicco D, Tampoia M, Virgintino D, Ribatti D, Serlenga L, Iannone F, Trojano M. Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy. *Muscle Nerve*. 2019 Sep;60(3):315-327. doi: 10.1002/mus.26608. Epub 2019 Jun 21. PMID: 31172530.

117: Lavie C, Rollet F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. *Mult Scler*. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20. PMID: 31081475.

118: Bassi M, Cilia S, Falautano M, Grobberio M, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Gasperini C, Minacapelli E, Patti F, Trojano M, Delle Fave A. Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. *Disabil Rehabil*.

2020 Dec;42(26):3780-3792. doi: 10.1080/09638288.2019.1610511. Epub 2019 May 6. PMID: 31056979.

119: Trojano M, Amato MP. Author Correction: Progress in multiple sclerosis - from diagnosis to therapy. *Nat Rev Neurol*. 2019 May;15(5):306. doi: 10.1038/s41582-019-0179-z. Erratum for: *Nat Rev Neurol*. 2018 Jan 31;14(2):72-74. PMID: 30936568.

120: Palazzo C, Buccoliero C, Mola MG, Abbrescia P, Nicchia GP, Trojano M, Frigeri A. AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding. *Acta Neuropathol Commun*. 2019 Apr 1;7(1):51. doi: 10.1186/s40478-019-0707-5. PMID: 30935410; PMCID: PMC6444679.

121: Girolamo F, Errede M, Longo G, Annese T, Alias C, Ferrara G, Morando S, Trojano M, Kerlero de Rosbo N, Uccelli A, Virgintino D. Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. *PLoS One*. 2019 Mar 14;14(3):e0213508. doi: 10.1371/journal.pone.0213508. PMID: 30870435; PMCID: PMC6417733.

122: Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratini P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group. Correction to: The Italian multiple sclerosis register. *Neurol Sci*. 2019 Apr;40(4):907. doi: 10.1007/s10072-019-03772-z. Erratum for: *Neurol Sci*. 2019 Jan;40(1):155-165. PMID: 30815752; PMCID: PMC6828204.

123: Sacco S, Benemei S, Cevoli S, Coppola G, Cortelli P, De Cesaris F, De Icco R, De Marco CM, Di Lorenzo C, Geppetti P, Manni A, Negro A, Ornello R, Pierangeli G, Pierelli F, Pellesi L, Pini LA, Pistoia F, Prudenzano MP, Russo A, Sances G, Taranta V, Tassorelli C, Tedeschi G, Trojano M, Martelletti P. Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. *J Headache Pain*. 2019 Feb 13;20(1):15. doi: 10.1186/s10194-019-0966-3. PMID: 30760199; PMCID: PMC6734365.

124: Pisani F, Simone L, Mola MG, De Bellis M, Mastrapasqua M, Ruggieri M, Trojano M, Nicchia GP, Svelto M, Frigeri A. Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies. *Cells*. 2019 Feb 2;8(2):119. doi: 10.3390/cells8020119. PMID: 30717425; PMCID: PMC6406603.

125: Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *Lancet Neurol*. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. PMID: 30663608.

- 126: Liguori M, Nuzziello N, Simone M, Amoroso N, Viterbo RG, Tangaro S, Consiglio A, Giordano P, Bellotti R, Trojano M. Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. *Brain Behav.* 2019 Feb;9(2):e01199. doi: 10.1002/brb3.1199. Epub 2019 Jan 17. PMID: 30656857; PMCID: PMC6379516.
- 127: Ruggieri S, Viggiano L, Annese T, Rubolino C, Gerbino A, De Zio R, Corsi P, Tamma R, Ribatti D, Errede M, Operto F, Margari L, Resta N, Di Tommaso S, Rosati J, Trojano M, Nico B. DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient. *Stem Cell Res Ther.* 2019 Jan 15;10(1):29. doi: 10.1186/s13287-018-1125-5. PMID: 30646960; PMCID: PMC6334379.
- 128: Brown JW, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA.* 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. Erratum in: *JAMA.* 2020 Apr 7;323(13):1318. PMID: 30644981; PMCID: PMC6439772.
- 129: Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrij M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13. PMID: 30636699.
- 130: Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. *Mult Scler Relat Disord.* 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3. PMID: 30623864.
- 131: Nuzziello N, Vilardo L, Pelucchi P, Consiglio A, Liuni S, Trojano M,

Liguori M. Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. *Int J Mol Sci.* 2018 Nov 20;19(11):3652. doi: 10.3390/ijms19113652. PMID: 30463275; PMCID: PMC6274935.

132: Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group. The Italian multiple sclerosis register. *Neurol Sci.* 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13. Erratum in: *Neurol Sci.* 2019 Apr;40(4):907. PMID: 30426289; PMCID: PMC6329744.

133: Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. *J Neurol Neurosurg Psychiatry.* 2019 Mar;90(3):261-267. doi: 10.1136/jnnp-2018-319208. Epub 2018 Nov 2. PMID: 30389778.

134: Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Bricchetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Oroglogas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seelldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Multiple sclerosis registries in Europe - An updated mapping survey. *Mult Scler Relat Disord.* 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. PMID: 30384204.

135: Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. *Eur J Neurol.* 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2. Erratum in: *Eur J Neurol.* 2020 Jun;27(6):1096. PMID: 30298572.

136: Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. *Mult Scler.* 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20. PMID: 30234431.

137: Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group. Trial of

Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. *N Engl J Med.* 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149. PMID: 30207920.

138: Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. *J Neurol Sci.* 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2. PMID: 30103975.

139: Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. *JAMA Neurol.* 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109. PMID: 30083762; PMCID: PMC6248114.

140: Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. *Mult Scler Relat Disord.* 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. PMID: 29860197.

141: Chitnis T, Giovannoni G, Trojano M. Complexity of MS management in the current treatment era. *Neurology.* 2018 Apr 24;90(17):761-762. doi: 10.1212/WNL.0000000000005399. PMID: 29686111.

142: Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurol.* 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. PMID: 29545067.

143: Iaffaldano P, Ribatti D, Trojano M. Natalizumab reduces serum pro-angiogenic activity in MS patients. *Neurol Sci.* 2018 Apr;39(4):725-731. doi: 10.1007/s10072-018-3266-9. Epub 2018 Feb 13. PMID: 29441483.

144: Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Pregnancy

decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. *Neurology*. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7. Erratum in: *Neurology*. 2020 Mar 17;94(11):504. PMID: 29438046.

145: Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. *Neurology*. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7. Erratum in: *Neurology*. 2020 Mar 17;94(11):504. PMID: 29438041.

146: Trojano M, Amato MP. Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy. *Nat Rev Neurol*. 2018 Jan 31;14(2):72-74. doi: 10.1038/nrneurol.2018.3. Erratum in: *Nat Rev Neurol*. 2019 May;15(5):306. PMID: 29384150.

147: Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. *Neurol Sci*. 2018 Feb;39(2):395. doi: 10.1007/s10072-017-3226-9. Erratum for: *Neurol Sci*. 2017 Oct;38(10):1849-1858. PMID: 29280018.

148: Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. PMID: 29275977.

149: Liguori M, Nuzziello N, Licciulli F, Consiglio A, Simone M, Viterbo RG, Creanza TM, Ancona N, Tortorella C, Margari L, Grillo G, Giordano P, Liuni S, Trojano M. Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. *Hum Mol Genet*. 2018 Jan 1;27(1):66-79. doi: 10.1093/hmg/ddx385. PMID: 29087462.

150: Manni A, Drenzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, Iaffaldano P, Trojano M, Paolicelli D. Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort. *Brain Behav*. 2017 Aug 29;7(10):e00804. doi: 10.1002/brb3.804. PMID: 29075564; PMCID: PMC5651388.

151: Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). *J Neurol.* 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23. PMID: 29063244; PMCID: PMC5688215.

152: Rosito S, Nicchia GP, Palazzo C, Lia A, Buccoliero C, Pisani F, Svelto M, Trojano M, Frigeri A. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. *J Cell Mol Med.* 2018 Feb;22(2):1236-1246. doi: 10.1111/jcmm.13401. Epub 2017 Oct 20. PMID: 29055082; PMCID: PMC5783885.

153: Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. *Brain.* 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. PMID: 29053779; PMCID: PMC5841198.

154: Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *Brain.* 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185. PMID: 29050389.

155: Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermodé A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. *Mult Scler.* 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: *Mult Scler.* 2017 Dec;23(14):NP1. PMID: 28857680.

156: Giovannetti AM, Giordano A, Pietrolongo E, Confalonieri P, De Luca G, Tortorella C, Trojano M, Messmer Uccelli M, Torri Clerici V, Gitto L, Köpke S, Borreani C, Heesen C, Solari A; ManTra project. Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. *BMJ Open.* 2017 Aug 23;7(8):e017254. doi: 10.1136/bmjopen-2017-017254. PMID:

28838904; PMCID: PMC5724224.

157: Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. *Neurology*. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9. PMID: 28794248; PMCID: PMC5589791.

158: Giannini M, Macchia L, Amati A, Lia A, Girolamo F, D'Abbicco D, Trojano M, Iannone F. A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis. *Scand J Rheumatol*. 2018 Jul;47(4):336-337. doi: 10.1080/03009742.2017.1350747. Epub 2017 Aug 5. PMID: 28780890.

159: Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. *Neurol Sci*. 2017 Oct;38(10):1849-1858. doi: 10.1007/s10072-017-3081-8. Epub 2017 Aug 2. Erratum in: *Neurol Sci*. 2017 Dec 26;: PMID: 28770366.

160: Trojano ML, Christopher PP, Pinals DA, Harnish A, Smelson D. Perceptions of voluntary consent among jail diverted veterans with co-occurring disorders. *Behav Sci Law*. 2017 Sep;35(5-6):408-417. doi: 10.1002/bsl.2299. Epub 2017 Aug 1. PMID: 28762534.

161: Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016ECTRIMS Focused Workshop Group. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. *Mult Scler*. 2018 Apr 1;24(5):590-603. doi: 10.1177/1352458516686847. PMID: 28671487.

162: Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Trojano M; Tysabri® Observational Program (TOP) Investigators. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. *Mult Scler*. 2018 Jun;24(7):963-973. doi: 10.1177/1352458517709619. Epub 2017 May 30. PMID: 28554238; PMCID: PMC6029149.

163: Tortorella C, Drenzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, D'Onghia M, Paolicelli D, Cuonzo FD, Gasperini C, Trojano M. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. *Mult Scler*. 2018 Jul;24(8):1039-1045.

doi: 10.1177/1352458517711774. Epub 2017 May 24. Erratum in: *Mult Scler*. 2019 Feb;25(2):302. PMID: 28537100.

164: Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. *Ann Neurol*. 2017 May;81(5):729-739. doi: 10.1002/ana.24938. PMID: 28439957.

165: Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. *Mult Scler*. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6. PMID: 28382837.

166: Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. *Neurology*. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22. PMID: 28228569.

167: Kalincik T, Brown JW, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. *Lancet Neurol*. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11. PMID: 28209331.

168: De Bellis M, Pisani F, Mola MG, Rosito S, Simone L, Buccoliero C, Trojano M, Nicchia GP, Svelto M, Frigeri A. Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. *Glia*. 2017 May;65(5):790-803. doi:

10.1002/glia.23126. Epub 2017 Feb 16. PMID: 28206694.

169: Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H. Treatment decisions in multiple sclerosis - insights from real-world observational studies. *Nat Rev Neurol*. 2017 Feb;13(2):105-118. doi: 10.1038/nrneurol.2016.188. Epub 2017 Jan 13. PMID: 28084327.

170: Paolicelli D, Manni A, D'Onghia M, Direnzo V, Iaffaldano P, Zoccolella S, Di Lecce V, Tortorella C, Specchia G, Trojano M. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients. *J Neuroimmunol*. 2017 Feb 15;303:75-80. doi: 10.1016/j.jneuroim.2016.12.012. Epub 2016 Dec 21. PMID: 28043652.

171: Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, Lechner-Scott J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. *Mult Scler*. 2017 Sep;23(10):1346-1357. doi: 10.1177/1352458516679893. Epub 2016 Nov 25. PMID: 27885062.

172: Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3. PMID: 27810919.

173: Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F, Cilia S, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Stampatori C, Trojano M, Viterbo RG, Amato MP. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. *Mult Scler*. 2017 Aug;23(9):1258-1267. doi: 10.1177/1352458516674367. Epub 2016 Oct 13. PMID: 27738090.

174: Vermersch P, Trojano M. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. *Eur Neurol*. 2016;76(5-6):216-226. doi: 10.1159/000449413. Epub 2016 Oct 13. Erratum in: *Eur Neurol*. 2016;76(5-6):226. PMID: 27732980.

175: Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E,

Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28. PMID: 27683916.

176: Benoit A, Durand-Dubief F, Amato MP, Portaccio E, Casey R, Roggerone S, Androdias G, Gignoux L, Ionescu I, Marrosu MG, Cocco E, Ghezzi A, Annovazzi P, Trojano M, Simone M, Marignier R, Confavreux C, Vukusic S. History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort. *Neurology*. 2016 Sep 27;87(13):1360-7. doi: 10.1212/WNL.0000000000003036. Epub 2016 Jul 27. PMID: 27466470.

177: Vermersch P, Berger T, Gold R, Lukas C, Rovira A, Meesen B, Chard D, Comabella M, Palace J, Trojano M. The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? *Mult Scler*. 2016 Aug;22(2 Suppl):18-33. doi: 10.1177/1352458516650739. PMID: 27465613.

178: Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group. Defining secondary progressive multiple sclerosis. *Brain*. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7. PMID: 27401521.

179: Paolicelli D, Iannazzo S, Santoni L, Iaffaldano A, Di Lecce V, Manni A, Lavolpe V, Tortorella C, D'Onghia M, Dorenzo V, Puma E, Trojano M. The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy. *PLoS One*. 2016 Jul 8;11(7):e0159214. doi: 10.1371/journal.pone.0159214. PMID: 27390865; PMCID: PMC4938389.

180: D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G, Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F. The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. *PLoS One*. 2016 Jun 27;11(6):e0157721. doi: 10.1371/journal.pone.0157721. PMID: 27348606; PMCID: PMC4922668.

181: Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzinger C,

Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group. Assessing response to interferon- β in a multicenter dataset of patients with MS. *Neurology*. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15. PMID: 27306626.

182: Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F, Slee M, Lugaresi A, Barnett M, Grammond P, Iuliano G, Hupperts R, Pucci E, Trojano M, Butzkueven H; MSBase Study Group. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. *J Neurol Neurosurg Psychiatry*. 2016 Oct;87(10):1133-7. doi: 10.1136/jnnp-2016-313760. Epub 2016 Jun 13. Erratum in: *J Neurol Neurosurg Psychiatry*. 2019 Apr;90(4):e2. PMID: 27298148.

183: Iaffaldano P, Viterbo RG, Trojano M. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. *J Neurol*. 2016 Aug;263(8):1620-5. doi: 10.1007/s00415-016-8177-1. Epub 2016 Jun 3. PMID: 27260295.

184: Paolicelli D, Manni A, Iaffaldano A, Di Lecce V, D'Onghia M, Iaffaldano P, Trojano M. The role of neutralizing antibodies to interferon- β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. *Eur J Clin Pharmacol*. 2016 Aug;72(8):1025-9. doi: 10.1007/s00228-016-2073-6. Epub 2016 Jun 1. PMID: 27251359.

185: Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. *J Neurol Neurosurg Psychiatry*. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9. PMID: 27160523; PMCID: PMC5013116.

186: Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Ann Neurol*. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1. PMID: 27145331.

187: Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci

E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H. Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. *Neurol Clin Pract*. 2016 Apr;6(2):102-115. doi: 10.1212/CPJ.0000000000000227. PMID: 27104064; PMCID: PMC4828679.

188: Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. Contribution of different relapse phenotypes to disability in multiple sclerosis. *Mult Scler*. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11. PMID: 27055805.

189: Paolicelli D, Cocco E, Di Lecce V, Drenzo V, Moiola L, Lanzillo R, Perini P, Malucchi S, Borriello G, Portaccio E, Panetta V, Fenu G, Sangalli F, Cacciaguerra L, Trojano M; TRACER Group. Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. *Expert Opin Drug Deliv*. 2016 Jun;13(6):799-805. doi: 10.1517/17425247.2016.1158161. Epub 2016 Mar 12. PMID: 26922837.

190: Trojano M. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. *Eur Neurol*. 2016;75 Suppl 1:4-8. doi: 10.1159/000444235. Epub 2016 Feb 23. PMID: 26901343.

191: Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold S, Cohen JA; attendees of the International Workshop on Comorbidity in Multiple Sclerosis. The challenge of comorbidity in clinical trials for multiple sclerosis. *Neurology*. 2016 Apr 12;86(15):1437-1445. doi: 10.1212/WNL.0000000000002471. Epub 2016 Feb 17. PMID: 26888986; PMCID: PMC4831041.

192: Pastò L, Portaccio E, Goretti B, Ghezzi A, Lori S, Hakiki B, Giannini M, Righini I, Razzolini L, Niccolai C, Moiola L, Falautano M, Simone M, Viterbo RG, Patti F, Cilia S, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society. The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. *Mult Scler*. 2016 Nov;22(13):1741-1749. doi: 10.1177/1352458516629559. Epub 2016 Feb 11. PMID: 26869527.

193: Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Fiest K, Reider N, Reingold S, Cohen JA; attendees of the International

Workshop on Comorbidity in Multiple Sclerosis. Recommendations for observational studies of comorbidity in multiple sclerosis. *Neurology*. 2016 Apr 12;86(15):1446-1453. doi: 10.1212/WNL.0000000000002474. Epub 2016 Feb 10. PMID: 26865523; PMCID: PMC4831039.

194: O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. *Neurology*. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: *Neurology*. 2016 Oct 4;87(14):1524. PMID: 26865517; PMCID: PMC4782117.

195: Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. *Eur J Neurol*. 2016 Apr;23(4):729-36. doi: 10.1111/ene.12929. Epub 2016 Jan 19. PMID: 26782663.

196: Wiendl H, Butzkueven H, Kappos L, Trojano M, Pellegrini F, Paes D, Zhang A, Belachew S; Tysabri® Observational Program (TOP) Investigators. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). *PLoS One*. 2016 Jan 15;11(1):e0144834. doi: 10.1371/journal.pone.0144834. PMID: 26771747; PMCID: PMC4714845.

197: Trojano M. Advances in the management of MS symptoms: real-life evidence. *Neurodegener Dis Manag*. 2015;5(6 Suppl):19-21. doi: 10.2217/nmt.15.66. PMID: 26611267.

198: Paolicelli D, Drenzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. *J Clin Pharmacol*. 2016 Jul;56(7):845-51. doi: 10.1002/jcph.670. Epub 2015 Dec 30. PMID: 26608223.

199: Pisani F, Settanni P, Rosito S, Mola MG, Iorio R, Tortorella C, Ruggieri M, Trojano M, Svelto M, Frigeri A, Nicchia GP. Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. *PLoS One*. 2015 Nov 24;10(11):e0143679. doi: 10.1371/journal.pone.0143679. PMID: 26599905; PMCID: PMC4658006.

200: Trojano M, Vila C. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study. *Eur Neurol*. 2015;74(3-4):178-85. doi: 10.1159/000441619. Epub 2015 Nov 17. PMID: 26571097.

201: Niccolai C, Portaccio E, Goretti B, Hakiki B, Giannini M, Pastò L, Righini I, Falautano M, Minacapelli E, Martinelli V, Incerti C, Nocentini U, Fenu G, Cocco E, Marrosu MG, Garofalo E, Ambra FI, Maddestra M, Consalvo M, Viterbo RG, Trojano M, Losignore NA, Zimatore GB, Pietrolongo E, Lugaresi A, Pippolo L, Roscio M, Ghezzi A, Castellano D, Stecchi S, Amato MP. A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. *BMC Neurol.* 2015 Oct 15;15:204. doi: 10.1186/s12883-015-0460-8. PMID: 26472052; PMCID: PMC4608308.

202: Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β 1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). *Mult Scler.* 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. PMID: 26466947.

203: Heesen C, Kasper J, Fischer K, Köpke S, Rahn A, Backhus I, Poettgen J, Vahter L, Drulovic J, Van Nunen A, Beckmann Y, Liethmann K, Giordano A, Fulcher G, Solari A; AutoMS-group. Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0)--Development of an Outcome Instrument for Educational Interventions. *PLoS One.* 2015 Oct 2;10(10):e0138364. doi: 10.1371/journal.pone.0138364. PMID: 26430887; PMCID: PMC4591974.

204: Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. *Brain.* 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11. PMID: 26362907.

205: Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H. Defining reliable disability outcomes in multiple sclerosis. *Brain.* 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10. PMID: 26359291.

206: Benedetti MD, Pugliatti M, D'Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Galeotti F, Massari M, Santuccio C, Raschetti R; ITANG Study Group. A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. *Neuroepidemiology.* 2015;45(2):90-9. doi: 10.1159/000438752.

Epub 2015 Aug 29. PMID: 26329724.

207: Rojas JI, Patrucco L, Trojano M, Lugaresi A, Izquierdo G, Butzkueven H, Jokubaitis V, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Rio ME, Van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Fernandez-Bolanos R, Poehlau D, Saladino ML, Braber-Moerland LD, Deri N, Oleschko-Arruda W, Cabrera-Gomez JA, Paine M, Vella N, Kister I, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, Bacile EAB, Santiago V, Cristiano E. Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. *Mult Scler J Exp Transl Clin.* 2015 Aug 17;1:2055217315600193. doi: 10.1177/2055217315600193. PMID: 28607702; PMCID: PMC5408755.

208: Bassi M, Falautano M, Cilia S, Goretti B, Grobberio M, Pattini M, Pietrolongo E, Viterbo RG, Amato MP, Benin M, Lugaresi A, Minacapelli E, Montanari E, Patti F, Trojano M, Delle Fave A. Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. *J Clin Psychol Med Settings.* 2016 Mar;23(1):33-52. doi: 10.1007/s10880-015-9425-8. PMID: 26216661.

209: Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. *Mult Scler.* 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21. PMID: 26199347.

210: Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Giuliani G, Barnett M, van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, La Spitaleri D, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, Lechner-Scott J. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. *PLoS One.* 2015 Jun 5;10(6):e0122686. doi: 10.1371/journal.pone.0122686. PMID: 26046348; PMCID: PMC4457630.

211: Del Piccolo L, Pietrolongo E, Radice D, Tortorella C, Confalonieri P, Pugliatti M, Lugaresi A, Giordano A, Heesen C, Solari A; AutoMS Project. Patient expression of emotions and neurologist responses in first multiple sclerosis consultations. *PLoS One.* 2015 Jun 1;10(6):e0127734. doi: 10.1371/journal.pone.0127734. PMID: 26030822; PMCID: PMC4452259.

212: Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Lugaresi A, Grammond P, Hupperts R, Cabrera-Gomez J, Oreja-Guevara C, Boz C, Giuliani G, Fernández-Bolaños R, Iuliano G, Lechner-Scott J, Verheul F, van Pesch V, Petkovska-Boskova T, Fiol M, Moore F, Cristiano E, Alroughani R, Bergamaschi R, Barnett M, Slee M, Vella N, Herbert J, Shaw C, Saladino ML, Amato MP, Liew D, Paolicelli D, Butzkueven H, Trojano M. Predictors of disability worsening in clinically isolated syndrome. *Ann Clin Transl Neurol*. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27. PMID: 26000321; PMCID: PMC4435703.

213: Zoccolella S, Spadafora P, Tortorella C, Amati A, Direnzo V, Trojano M. A rare case of multiple sclerosis and McArdle disease. *Neurol Sci*. 2015 Sep;36(9):1721-3. doi: 10.1007/s10072-015-2249-3. Epub 2015 May 19. PMID: 25987006.

214: Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, Lechner-Scott J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H. Comparative efficacy of switching to natalizumab in active multiple sclerosis. *Ann Clin Transl Neurol*. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27. PMID: 25909083; PMCID: PMC4402083.

215: Paolicelli D, Manni A, Direnzo V, D'Onghia M, Tortorella C, Zoccolella S, Trojano M. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study. *J Clin Pharmacol*. 2015 Oct;55(10):1131-6. doi: 10.1002/jcph.519. Epub 2015 Jun 17. PMID: 25903516.

216: Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, Lechner-Scott J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M. BREMSO: a simple score to predict early the natural course of multiple sclerosis. *Eur J Neurol*. 2015 Jun;22(6):981-9. doi: 10.1111/ene.12696. Epub 2015 Mar 25. PMID: 25808578.

217: Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; International Clinically Isolated Syndrome Study Group. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. *J Neurol Neurosurg Psychiatry*. 2016 Feb;87(2):126-9. doi: 10.1136/jnnp-2014-309690. Epub 2015 Feb 25. PMID: 25716934.

218: Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N,

Thouvenot E, Iaffaldano P, Drenzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Lulfriú S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmstrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. *Mult Scler*. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13. PMID: 25680984.

219: He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugesesi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. *JAMA Neurol*. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: *JAMA Neurol*. 2015 Aug;72(8):950. PMID: 25665031.

220: Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. *Mult Scler*. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26. PMID: 25623244; PMCID: PMC4361468.

221: De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. *Acta Neurol Scand*. 2015 May;131(5):336-40. doi: 10.1111/ane.12364. Epub 2015 Jan 18. PMID: 25598313.

222: Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. *Mult Scler*. 2015 Mar;21(3):305-17. doi: 10.1177/1352458514564487. Epub 2015 Jan 12. PMID: 25583845; PMCID: PMC4429164.

223: Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugesesi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R,

Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. *Ann Neurol*. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17. PMID: 25546031.

224: Ribatti D, Iaffaldano P, Marinaccio C, Trojano M. First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients. *Clin Exp Med*. 2016 Feb;16(1):103-7. doi: 10.1007/s10238-014-0334-1. Epub 2014 Dec 25. PMID: 25539984.

225: Marrie RA, Reider N, Stuve O, Trojano M, Sorensen PS, Cutter GR, Reingold SC, Cohen J. The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. *Mult Scler*. 2015 Mar;21(3):332-41. doi: 10.1177/1352458514564488. Epub 2014 Dec 23. PMID: 25538150; PMCID: PMC4429162.

226: Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. *Mult Scler*. 2015 Mar;21(3):294-304. doi: 10.1177/1352458514564489. Epub 2014 Dec 22. PMID: 25533302; PMCID: PMC4429168.

227: Marrie RA, Reider N, Cohen J, Trojano M, Sorensen PS, Cutter G, Reingold S, Stuve O. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. *Mult Scler*. 2015 Mar;21(3):342-9. doi: 10.1177/1352458514564486. Epub 2014 Dec 22. PMID: 25533301; PMCID: PMC4429167.

228: Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. *Mult Scler*. 2015 Mar;21(3):318-31. doi: 10.1177/1352458514564485. Epub 2014 Dec 22. PMID: 25533300; PMCID: PMC4404402.

229: Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. *Mult Scler*. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22. PMID: 25533299; PMCID: PMC4429166.

230: Trojano M, Tortorella C. MS and related disorders: looking for markers of phenotypes. *Lancet Neurol*. 2015 Jan;14(1):11-3. doi: 10.1016/S1474-4422(14)70291-1. PMID: 25496884.

231: Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P,

Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand'Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, Lechner-Scott J, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; MSBase Study Group. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. *Mult Scler*. 2015 Aug;21(9):1159-71. doi: 10.1177/1352458514559865. Epub 2014 Dec 5. PMID: 25480857.

232: Trojano M. The use of multiple population-based data sources for estimating MS sex ratio trends over time. *Mult Scler*. 2014 Oct;20(12):1551-2. doi: 10.1177/1352458514536088. PMID: 25344587.

233: Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. *Ann Neurol*. 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20. PMID: 25283272.

234: Trojano M, Celiuș EG, Donzé C, Izquierdo G, Patti F, Pöhlau D. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights. *Eur Neurol*. 2014;72 Suppl 1:15-9. doi: 10.1159/000367619. Epub 2014 Sep 26. PMID: 25278119.

235: Amato MP, Goretti B, Ghezzi A, Hakiki B, Niccolai C, Lori S, Moiola L, Falautano M, Viterbo RG, Patti F, Cilia S, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Portaccio E, Trojano M; MS Study Group of the Italian Neurological Society. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. *Neurology*. 2014 Oct 14;83(16):1432-8. doi: 10.1212/WNL.0000000000000885. Epub 2014 Sep 12. PMID: 25217060.

236: Goretti B, Niccolai C, Hakiki B, Sturchio A, Falautano M, Minacapelli E, Martinelli V, Incerti C, Nocentini U, Murgia M, Fenu G, Cocco E, Marrosu MG, Garofalo E, Ambra FI, Maddestra M, Consalvo M, Viterbo RG, Trojano M, Losignore NA, Zimatore GB, Pietrolongo E, Lugaresi A, Langdon D, Portaccio E, Amato MP. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. *BMC Neurol*. 2014 Sep 10;14:171. doi: 10.1186/s12883-014-0171-6. PMID: 25204350; PMCID: PMC4172942.

237: Tortorella C, Drenzo V, Taurisano P, Romano R, Ruggieri M, Zoccolella S, Mastrapasqua M, Popolizio T, Blasi G, Bertolino A, Trojano M. Cerebrospinal

fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. *Mult Scler*. 2015 Apr;21(4):396-401. doi: 10.1177/1352458514546789. Epub 2014 Aug 28. PMID: 25168208.

238: Liguori M, Quattieri A, Tortorella C, Direnzo V, Bagalà A, Mastrapasqua M, Spadafora P, Trojano M. Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. *PLoS One*. 2014 Aug 6;9(8):e103984. doi: 10.1371/journal.pone.0103984. PMID: 25098164; PMCID: PMC4123901.

239: Girolamo F, Coppola C, Ribatti D, Trojano M. Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. *Acta Neuropathol Commun*. 2014 Jul 22;2:84. doi: 10.1186/s40478-014-0084-z. PMID: 25047180; PMCID: PMC4149233.

240: Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). *JAMA Neurol*. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. PMID: 24977406.

241: Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, Mancardi GL, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. *BMC Neurol*. 2014 May 26;14:114. doi: 10.1186/1471-2377-14-114. PMID: 24884599; PMCID: PMC4059028.

242: Flachenecker P, Buckow K, Pugliatti M, Kes VB, Battaglia MA, Boyko A, Confavreux C, Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L, Kasilingam E, Koch-Henriksen N, Kuhle J, Lepore V, Middleton R, Myhr KM, Ologos A, Otero S, Pitschnau-Michel D, Rienhoff O, Sastre-Garriga J, Schyns-Liharska T, Sutovic D, Thalheim C, Trojano M, Vlasov YV, Yaldizli O; EUREMS Consortium. Multiple sclerosis registries in Europe - results of a systematic survey. *Mult Scler*. 2014 Oct;20(11):1523-32. doi: 10.1177/1352458514528760. Epub 2014 Apr 28. PMID: 24777278.

243: Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, Girard M, Lugaresi A, Grammond P, Grand'Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray

O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group. Risk of relapse phenotype recurrence in multiple sclerosis. *Mult Scler*. 2014 Oct;20(11):1511-22. doi: 10.1177/1352458514528762. Epub 2014 Apr 28. PMID: 24777276.

244: Iaffaldano P, Viterbo RG, Goretti B, Portaccio E, Amato MP, Trojano M. Emotional and neutral verbal memory impairment in Multiple Sclerosis. *J Neurol Sci*. 2014 Jun 15;341(1-2):28-31. doi: 10.1016/j.jns.2014.03.038. Epub 2014 Mar 26. PMID: 24713509.

245: Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology*. 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.0000000000000283. Epub 2014 Mar 7. PMID: 24610329; PMCID: PMC4001200.

246: Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. *J Neurol Neurosurg Psychiatry*. 2014 Nov;85(11):1190-7. doi: 10.1136/jnnp-2013-306936. Epub 2014 Feb 14. PMID: 24532785; PMCID: PMC4215289.

247: Capra R, Battaglia MA, Gaudio A, Lopes L, Paolicelli D, Paoloni M, Pozzilli C, Santilli V, Solaro C, Trojano M. The MoSt Project--more steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. *J Neurol*. 2014 Mar;261(3):526-32. doi: 10.1007/s00415-013-7230-6. Epub 2014 Jan 22. PMID: 24449060.

248: Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. *Mult Scler*. 2014 Apr;20(5):527-36. doi: 10.1177/1352458513519840. Epub 2014 Jan 20. PMID: 24446387; PMCID: PMC5458871.

249: Giordano A, Lugaresi A, Confalonieri P, Granella F, Radice D, Trojano M, Martinelli V, Solari A; SIMS-Practice group. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. *Mult Scler*. 2014 Aug;20(9):1234-43. doi: 10.1177/1352458513519180. Epub 2014 Jan 13. PMID: 24421305.

250: Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, Patti F, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society. Postpartum relapses increase the risk

of disability progression in multiple sclerosis: the role of disease modifying drugs. *J Neurol Neurosurg Psychiatry*. 2014 Aug;85(8):845-50. doi: 10.1136/jnnp-2013-306054. Epub 2014 Jan 8. PMID: 24403285.

251: Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Iorio M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, Malucchi S; Italian Multiple Sclerosis Study group. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. *Neurol Sci*. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29. Erratum in: *Neurol Sci*. 2014 Oct;35(10):1645-6. Troiano, Maria [corrected to Trojano, Maria]. PMID: 24374787.

252: Bassi M, Falautano M, Cilia S, Goretti B, Grobberio M, Pattini M, Pietrolongo E, Viterbo RG, Amato MP, Benin M, Lugaresi A, Martinelli V, Montanari E, Patti F, Trojano M, Delle Fave A. The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. *J Neurol Sci*. 2014 Feb 15;337(1-2):67-73. doi: 10.1016/j.jns.2013.11.018. Epub 2013 Nov 19. PMID: 24289888.

253: Ciciarello F, Mandolesi S, Galeandro AI, Marceca A, Rossi M, Fedele F, Gesualdo M, Cortese F, Zito A, Federico F, Livrea P, Trojano M, Scicchitano P, Ciccone MM. Age-related vascular differences among patients suffering from multiple sclerosis. *Curr Neurovasc Res*. 2014 Feb;11(1):23-30. doi: 10.2174/1567202610666131125000506. PMID: 24274909.

254: Pisani F, Sparaneo A, Tortorella C, Ruggieri M, Trojano M, Mola MG, Nicchia GP, Frigeri A, Svelto M. Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. *PLoS One*. 2013 Nov 15;8(11):e79185. doi: 10.1371/journal.pone.0079185. PMID: 24260168; PMCID: PMC3829826.

255: Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkowska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. *Brain*. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18. PMID: 24142147.

256: Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S,

Plant A, Picconi O; COGIMUS Study Group. Subcutaneous interferon β -1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. *PLoS One*. 2013 Aug 30;8(8):e74111. doi: 10.1371/journal.pone.0074111. PMID: 24137499; PMCID: PMC3796707.

257: Tortorella C, Drenzo V, D'Onghia M, Trojano M. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. *Neurology*. 2013 Oct 15;81(16):1470-1. doi: 10.1212/WNL.0b013e3182a84179. PMID: 24127190.

258: Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, van Pesch V, Amato MP, Iuliano G, Slee M, Verheul F, Cristiano E, Fernández-Bolaños R, Poehlau D, Saladino ML, Deri N, Cabrera-Gomez J, Vella N, Herbert J, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkovska-Boskova T, McDonnell G, Hawkins S, Kee F, Butzkueven H; MSBase study group. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. *Mult Scler*. 2014 May;20(6):739-46. doi: 10.1177/1352458513507816. Epub 2013 Oct 9. PMID: 24107309.

259: Goretti B, Viterbo RG, Portaccio E, Niccolai C, Hakiki B, Piscolla E, Iaffaldano P, Trojano M, Amato MP. Anxiety state affects information processing speed in patients with multiple sclerosis. *Neurol Sci*. 2014 Apr;35(4):559-63. doi: 10.1007/s10072-013-1544-0. Epub 2013 Sep 27. PMID: 24072658.

260: Comi G, Battaglia MA, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, Salvetti M, Sormani MP, Tesio L, Stolz E, Zaratin P, Mancardi G; CoSMo Collaborative Study Group. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. *Mult Scler*. 2013 Oct;19(11):1508-17. doi: 10.1177/1352458513501231. Epub 2013 Sep 6. PMID: 24014572.

261: Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. *Brain Behav Immun*. 2014 Jan;35:176-81. doi: 10.1016/j.bbi.2013.08.009. Epub 2013 Aug 30. PMID: 23994630.

262: Amato MP, Goretti B, Viterbo RG, Portaccio E, Niccolai C, Hakiki B, Iaffaldano P, Trojano M. Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. *Mult Scler*. 2014 Jan;20(1):91-8. doi: 10.1177/1352458513501571. Epub 2013 Aug 19. PMID: 23959713.

263: Filippi M, Rocca MA, Bastianello S, Comi G, Gallo P, Gallucci M, Ghezzi A, Marrosu MG, Minonzio G, Pantano P, Pozzilli C, Tedeschi G, Trojano M, Falini A, De Stefano N; Neuroimaging and MS Study Groups of the Italian Society of

Neurology; Functional Neuroradiology Section of the Italian Association of Neuroradiology. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. *Neurol Sci.* 2013 Dec;34(12):2085-93. doi: 10.1007/s10072-013-1485-7. Epub 2013 Jul 5. PMID: 23828372.

264: Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, Lechner-Scott J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkowska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. *PLoS One.* 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. PMID: 23704913; PMCID: PMC3660604.

265: Viterbo RG, Iaffaldano P, Trojano M. Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. *J Neurol Sci.* 2013 Jul 15;330(1-2):56-60. doi: 10.1016/j.jns.2013.04.004. Epub 2013 Apr 28. PMID: 23628466.

266: Pietrolongo E, Giordano A, Kleinfeld M, Confalonieri P, Lugaresi A, Tortorella C, Pugliatti M, Radice D, Goss C, Heesen C, Solari A; AutoMS group. Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. *PLoS One.* 2013;8(4):e60721. doi: 10.1371/journal.pone.0060721. Epub 2013 Apr 2. PMID: 23565270; PMCID: PMC3614559.

267: Galeotti F, Massari M, D'Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Benedetti MD, Pugliatti M, Santuccio C, Raschetti R; ITANG study group. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. *Eur J Epidemiol.* 2013 May;28(5):433-44. doi: 10.1007/s10654-013-9797-8. Epub 2013 Mar 31. PMID: 23543123; PMCID: PMC3672511.

268: Girolamo F, Lia A, Amati A, Strippoli M, Coppola C, Virgintino D, Roncali L, Toscano A, Serlenga L, Trojano M. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. *Neuropathol Appl Neurobiol.* 2013 Dec;39(7):736-49. doi: 10.1111/nan.12040. PMID: 23452291.

269: Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSo) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. *Mult Scler.* 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27. PMID:

23447359.

270: Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavalpe V, Trojano M. The impact of neutralizing antibodies on the risk of disease worsening in interferon β -treated relapsing multiple sclerosis: a 5 year post-marketing study. *J Neurol*. 2013 Jun;260(6):1562-8. doi: 10.1007/s00415-012-6829-3. Epub 2013 Feb 17. PMID: 23417273.

271: Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. *Mult Scler*. 2013 Jul;19(8):1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11. PMID: 23401129.

272: Trojano M. Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword. *Expert Rev Neurother*. 2013 Feb;13(3 Suppl 1):1. doi: 10.1586/ern.13.2. PMID: 23369052.

273: Tortorella C, Romano R, Direnzo V, Taurisano P, Zoccolella S, Iaffaldano P, Fazio L, Viterbo R, Popolizio T, Blasi G, Bertolino A, Trojano M. Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. *Mult Scler*. 2013 Aug;19(9):1153-60. doi: 10.1177/1352458512473671. Epub 2013 Jan 17. PMID: 23329700.

274: Pugliatti M, Eskic D, Mikolcić T, Pitschnau-Michel D, Myhr KM, Sastre-Garriga J, Otero S, Wieczynska L, Torje C, Holloway E, Rienhoff O, Friede T, Buckow K, Ellenberger D, Hillert J, Glaser A, Flachenecker P, Fuge J, Schyns-Liharska T, Kasilingam E, Moretti A, Thalheim C; EUREMS Consortium. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. *Acta Neurol Scand Suppl*. 2012;(195):24-30. doi: 10.1111/ane.12024. PMID: 23278653.

275: Pastò L, Portaccio E, Ghezzi A, Hakiki B, Giannini M, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi GL, Solaro C, Totaro R, Tola MR, Di Tommaso V, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. *BMC Neurol*. 2012 Dec 31;12:165. doi: 10.1186/1471-2377-12-165. PMID: 23276328; PMCID: PMC3544735.

276: Messmer Uccelli M, Traversa S, Trojano M, Viterbo RG, Ghezzi A, Signori A. Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple. *J Neurol Sci*. 2013 Jan 15;324(1-2):100-5. doi: 10.1016/j.jns.2012.10.010. Epub 2012 Nov 8. PMID: 23140806.

277: Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Drenzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group. Geographical variations in sex ratio trends over time in multiple sclerosis. *PLoS One*. 2012;7(10):e48078. doi: 10.1371/journal.pone.0048078. Epub 2012 Oct 25. PMID: 23133550; PMCID: PMC3485003.

278: Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. *BMC Neurol*. 2012 Oct 22;12:124. doi: 10.1186/1471-2377-12-124. PMID: 23088447; PMCID: PMC3487812.

279: Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato MP, Grand'maison F, Butzkueven H, Marrosu M, Duquette P, Comi G, Izquierdo G, Grammond P, Lus G, Petersen T, Bergamaschi R, Giuliani G, Boz C, Coniglio G, Van Pesch V, Lechner-Scott J, Cavalla P, Granella F, Avolio C, Fiol M, Poehlau D, Saladino ML, Gallo P, Deri N, Oleschko Arruda W, Paine M, Ferro M, Barnett M, Cabrera-Gomez JA, Slee M, Moore F, Shaw C, Petkovska-Boskova T, Rutherford M, Engelsens O, Damoiseaux J, Hupperts R. Fluctuations of MS births and UV-light exposure. *Acta Neurol Scand*. 2013 May;127(5):301-8. doi: 10.1111/ane.12007. Epub 2012 Sep 12. PMID: 22970985.

280: Zoccolella S, Tortorella C, Iaffaldano P, Drenzo V, D'Onghia M, Luciannatelli E, Paolicelli D, Livrea P, Trojano M. Low serum urate levels are associated to female gender in multiple sclerosis patients. *PLoS One*. 2012;7(7):e40608. doi: 10.1371/journal.pone.0040608. Epub 2012 Jul 27. PMID: 22848387; PMCID: PMC3407193.

281: Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; MSBasis Study Group. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. *PLoS One*. 2012;7(6):e38661. doi: 10.1371/journal.pone.0038661. Epub 2012 Jun 29. PMID: 22768046; PMCID: PMC3387159.

282: Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, Romani A, Tortorella C, Portaccio E, D'Onghia M, Garberi F, Bargiggia V, Trojano

M. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult Scler.* 2016 Nov;22(13):1732-1740. doi: 10.1177/1352458512445941. Epub 2012 May 31. PMID: 22653657.

283: Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, Drenzo V, D'Onghia M, Zoccolella S, Amato MP, Trojano M. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. *PLoS One.* 2012;7(4):e35843. doi: 10.1371/journal.pone.0035843. Epub 2012 Apr 25. PMID: 22558238; PMCID: PMC3338465.

284: de Tommaso M, Ceci E, Pica C, Trojano M, Delussi M, Franco G, Livrea P, Ruggieri M. Serum levels of N-acetyl-aspartate in migraine and tension-type headache. *J Headache Pain.* 2012 Jul;13(5):389-94. doi: 10.1007/s10194-012-0448-3. Epub 2012 Apr 17. PMID: 22527035; PMCID: PMC3381063.

285: Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators. Increasing age at disability milestones among MS patients in the MSBase Registry. *J Neurol Sci.* 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14. PMID: 22507751.

286: Ciccone MM, Galeandro AI, Scicchitano P, Zito A, Gesualdo M, Sassari M, Cortese F, Dachille A, Carbonara R, Federico F, Livrea P, Trojano M. Multigate quality Doppler profiles and morphological/hemodynamic alterations in multiple sclerosis patients. *Curr Neurovasc Res.* 2012 May;9(2):120-7. doi: 10.2174/156720212800410849. PMID: 22475396.

287: Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, Livrea P, Lecchini S, Marino F. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon- β therapy. *Neuroimmunomodulation.* 2012;19(5):283-92. doi: 10.1159/000336981. Epub 2012 Apr 3. PMID: 22472872.

288: Zoccolella S, Tortorella C, Iaffaldano P, Drenzo V, D'Onghia M, Paolicelli D, Livrea P, Trojano M. Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. *J Neurol.* 2012 Oct;259(10):2105-10. doi: 10.1007/s00415-012-6464-z. Epub 2012 Mar 16. PMID: 22421956.

289: Caragnano M, Tortorella P, Bergami A, Ruggieri M, Livrea P, Specchio LM, Martino G, Trojano M, Furlan R, Avolio C. Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. *J Neuroimmunol.* 2012 Apr;245(1-2):93-7. doi: 10.1016/j.jneuroim.2012.02.002. Epub 2012 Feb 26. PMID: 22370183.

290: Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. *J Neurol Neurosurg Psychiatry*. 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28. PMID: 22205675.

291: Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand'Maison F, Gomez JA, Izquierdo G, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Boz C, Giuliani G, van Pesch V, Iuliano G, Fiol M, Cristiano E, Verheul F, Saladino ML, Slee M, Barnett M, Deri N, Flechter S, Vella N, Shaw C, Herbert J, Moore F, Petkovska-Boskova T, Jokubaitis V, Butzkueven H; MSBase study group. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. *Mult Scler*. 2012 Jul;18(7):974-82. doi: 10.1177/1352458511431729. Epub 2011 Dec 20. PMID: 22185806.

292: Iaffaldano P, Lucchese G, Trojano M. Treating multiple sclerosis with natalizumab. *Expert Rev Neurother*. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. PMID: 22091593.

293: Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. *Neurology*. 2011 Nov 22;77(21):1887-95. doi: 10.1212/WNL.0b013e318238ee00. Epub 2011 Nov 9. PMID: 22076543.

294: Borreani C, Giordano A, Falautano M, Lugaresi A, Martinelli V, Granella F, Tortorella C, Plasmati I, Radaelli M, Farina D, Dalla Bella E, Bianchi E, Acquarone N, Miccinesi G, Solari A; SIMS-Trial group. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial. *Health Expect*. 2014 Feb;17(1):36-48. doi: 10.1111/j.1369-7625.2011.00736.x. Epub 2011 Nov 1. PMID: 22040528; PMCID: PMC5060699.

295: Ruggieri M, Serpino C, Ceci E, Scirucchio V, Franco G, Pica C, Trojano M, Livrea P, de Tommaso M. Serum levels of N-acetylaspartate in Huntington's disease: preliminary results. *Mov Disord*. 2012 Feb;27(2):329-30. doi: 10.1002/mds.23974. Epub 2011 Oct 28. PMID: 22038921.

296: Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S,

Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β -1a in the COGNitive Impairment in MULTiple Sclerosis (COGIMUS) study. *BMC Neurol.* 2011 Oct 14;11:125. doi: 10.1186/1471-2377-11-125. PMID: 21999142; PMCID: PMC3214173.

297: O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med.* 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656. PMID: 21991951.

298: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Grimaldi LM; COGIMUS study group. Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β -1a: results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study (II). *Qual Life Res.* 2012 Sep;21(7):1111-21. doi: 10.1007/s11136-011-0021-6. Epub 2011 Sep 28. PMID: 21953022.

299: Goretti B, Portaccio E, Ghezzi A, Lori S, Moiola L, Falautano M, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Cappiello S, Comi G, Trojano M, Amato MP; Multiple Sclerosis Study Group of the Italian Neurological Society. Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. *Mult Scler.* 2012 Mar;18(3):329-34. doi: 10.1177/1352458511420846. Epub 2011 Aug 15. PMID: 21844064.

300: Portaccio E, Ghezzi A, Hakiki B, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society. Breastfeeding is not related to postpartum relapses in multiple sclerosis. *Neurology.* 2011 Jul 12;77(2):145-50. doi: 10.1212/WNL.0b013e318224afc9. Epub 2011 Jul 6. PMID: 21734184.

301: Girolamo F, Ferrara G, Strippoli M, Rizzi M, Errede M, Trojano M, Perris R, Roncali L, Svelto M, Mennini T, Virgintino D. Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. *Neurobiol Dis.* 2011 Sep;43(3):678-89. doi: 10.1016/j.nbd.2011.05.021. Epub 2011 Jun 6. PMID: 21679768.

302: Martino D, Chiarotti F, Buttiglione M, Cardona F, Creti R, Nardocci N, Orefici G, Veneselli E, Rizzo R; Italian Tourette Syndrome Study Group. The relationship between group A streptococcal infections and Tourette syndrome: a study on a large service-based cohort. *Dev Med Child Neurol.* 2011 Oct;53(10):951-7. doi: 10.1111/j.1469-8749.2011.04018.x. Epub 2011 Jun 17. PMID: 21679362.

- 303: Tortorella C, Ruggieri M, Di Monte E, Ceci E, Iaffaldano P, Direnzo V, Mastrapasqua M, Frigeri A, Amato MP, Hakiki B, Ghezzi A, Lugaresi A, De Luca G, Patti F, D'Amico E, Sola P, Simone AM, Svelto M, Livrea P, Trojano M. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. *J Neurol Neurosurg Psychiatry*. 2011 Dec;82(12):1355-9. doi: 10.1136/jnnp.2011.241836. Epub 2011 May 27. PMID: 21622936.
- 304: Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, Radice D, Solari A; SIMS-Trial group. Anxiety and depression in multiple sclerosis patients around diagnosis. *J Neurol Sci*. 2011 Aug 15;307(1-2):86-91. doi: 10.1016/j.jns.2011.05.008. Epub 2011 May 31. PMID: 21621796.
- 305: Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurol*. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13. PMID: 21571593.
- 306: Trojano M. Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis. *Nat Rev Neurol*. 2011 May;7(5):251-2. doi: 10.1038/nrneurol.2011.55. Epub 2011 Apr 12. PMID: 21537354.
- 307: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study. *Mult Scler*. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18. PMID: 21502310.
- 308: Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, Di Renzo V, D'Onghia M. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? *Neurol Clin*. 2011 May;29(2):309-21. doi: 10.1016/j.ncl.2010.12.008. PMID: 21439443.
- 309: Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M; French-Italian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. *J Neurol Neurosurg Psychiatry*. 2011 Dec;82(12):1344-50. doi: 10.1136/jnnp.2010.229724. Epub 2011 Mar 24. PMID: 21436229.
- 310: Ruggieri M, Tortorella C, Ceci E, Paolicelli D, Solfrizzi V, Di Bitonto G, Pica C, Mastrapasqua M, Livrea P, Trojano M. Age-related changes of serum N-acetyl-aspartate in healthy controls. *Age Ageing*. 2011 May;40(3):391-5. doi: 10.1093/ageing/afr021. Epub 2011 Mar 20. PMID: 21422012.

- 311: Patti F, Amato MP, Trojano M, Solaro C, Pappalardo A, Zipoli V, Portaccio E, Paolicelli D, Paolillo A, Mennini FS, Marcellusi A, Ricci C, Battaglia MA. Multiple sclerosis in Italy: cost-of-illness study. *Neurol Sci.* 2011 Oct;32(5):787-94. doi: 10.1007/s10072-011-0499-2. Epub 2011 Mar 16. PMID: 21409509.
- 312: Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G; MS-SIN Study Group. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. *Neurol Sci.* 2011 Apr;32(2):351-8. doi: 10.1007/s10072-010-0469-0. PMID: 21234775.
- 313: Pisani F, Mastrototaro M, Rossi A, Nicchia GP, Tortorella C, Ruggieri M, Trojano M, Frigeri A, Svelto M. Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. *J Biol Chem.* 2011 Mar 18;286(11):9216-24. doi: 10.1074/jbc.M110.123000. Epub 2011 Jan 6. PMID: 21212277; PMCID: PMC3059066.
- 314: Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M; MS Study Group of the Italian Neurological Society. Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. *Neurology.* 2010 Nov 16;75(20):1794-802. doi: 10.1212/WNL.0b013e3181fd62bb. PMID: 21079181.
- 315: Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, Falautano M, De Caro MF, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Portaccio E, Trojano M; Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. *Neurology.* 2010 Sep 28;75(13):1134-40. doi: 10.1212/WNL.0b013e3181f4d821. PMID: 20876467.
- 316: Solari A, Martinelli V, Trojano M, Lugaresi A, Granella F, Giordano A, Messmer Uccelli M, D'Alessandro R, Pucci E, Confalonieri P, Borreani C; SIMS-Trial group. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. *Mult Scler.* 2010 Nov;16(11):1393-405. doi: 10.1177/1352458510380417. Epub 2010 Sep 21. PMID: 20858692.
- 317: Solari A, Mattarozzi K, Vignatelli L, Giordano A, Russo PM, Uccelli MM, D'Alessandro R; SIMS-Trial group; GERONIMUS group. Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. *Mult Scler.* 2010 Oct;16(10):1237-47. doi:

10.1177/1352458510376178. Epub 2010 Sep 2. PMID: 20813775.

318: Trojano M. Improving combination trials for multiple sclerosis. *Lancet Neurol.* 2010 Jul;9(7):646-7. doi: 10.1016/S1474-4422(10)70134-4. Epub 2010 Jun 9. PMID: 20542737.

319: Goretti B, Ghezzi A, Portaccio E, Lori S, Zipoli V, Razzolini L, Moiola L, Falautano M, De Caro MF, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M, Amato MP; Study Group of the Italian Neurological Society. Psychosocial issue in children and adolescents with multiple sclerosis. *Neurol Sci.* 2010 Aug;31(4):467-70. doi: 10.1007/s10072-010-0281-x. Epub 2010 May 8. PMID: 20454820.

320: Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *J Neurol Sci.* 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. PMID: 20236661.

321: Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. PMID: 20089960.

322: Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. PMID: 20089954.

323: Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. *Mult Scler.* 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7. PMID: 19995846.

324: Giordano A, Uccelli MM, Pucci E, Martinelli V, Borreani C, Lugaresi A, Trojano M, Granella F, Confalonieri P, Radice D, Solari A; SIMS-Trial group. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. *Mult Scler.* 2010 Jan;16(1):100-11. doi: 10.1177/1352458509352865. Epub 2009 Dec 7. PMID: 19995834.

325: Iaffaldano P, D'Onghia M, Trojano M. Safety profile of Tysabri: international risk management plan. *Neurol Sci.* 2009 Oct;30 Suppl 2:S159-62.

doi: 10.1007/s10072-009-0148-1. PMID: 19882366.

326: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V. observational studies: propensity score analysis of non-randomized data. *Int MS J*. 2009 Sep;16(3):90-7. PMID: 19878631.

327: Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuč E, Paraskevas GP, Pirttilä T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen CE. Neurofilament ELISA validation. *J Immunol Methods*. 2010 Jan 31;352(1-2):23-31. doi: 10.1016/j.jim.2009.09.014. Epub 2009 Oct 24. PMID: 19857497.

328: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. *Ann Neurol*. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757. PMID: 19847899.

329: Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, Confavreux C; Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis Study Group. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. *J Neurol Sci*. 2009 Nov 15;286(1-2):114-8. doi: 10.1016/j.jns.2009.08.056. Epub 2009 Sep 15. PMID: 19758607.

330: O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol*. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: *Lancet Neurol*. 2009 Nov;8(11):981. Erratum in: *Lancet Neurol*. 2011 Feb;10(2):115. Erratum in: *Lancet Neurol*. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P]. PMID: 19729344.

- 331: Paolicelli D, Drenzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. *Biologics*. 2009;3:369-76. Epub 2009 Jul 13. PMID: 19707422; PMCID: PMC2726074.
- 332: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Drenzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. *J Neurol Sci*. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16. PMID: 19615696.
- 333: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. *Mult Scler*. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544. PMID: 19542262.
- 334: Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. *Neurol Sci*. 2009 Jun;30(3):193-9. doi: 10.1007/s10072-009-0083-1. Epub 2009 Apr 22. PMID: 19387545.
- 335: Trojano M, Avolio C. Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? *J Neurol Neurosurg Psychiatry*. 2009 May;80(5):469. doi: 10.1136/jnnp.2008.165217. PMID: 19372286.
- 336: Hussain H, Usman A, Raza Q, Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, Moiola L, Falautano M, De Caro MF, Lopez M, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M. Cognitive and psychosocial features of childhood and juvenile MS. *Neurology*. 2009 Mar 31;72(13):1189; author reply 1189-90. doi: 10.1212/01.wnl.0000346320.61178.56. PMID: 19332701.
- 337: Portaccio E, Goretti B, Lori S, Zipoli V, Centorrino S, Ghezzi A, Patti F, Bianchi V, Comi G, Trojano M, Amato MP; Multiple Sclerosis Study Group of the Italian Neurological Society. The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. *Mult Scler*. 2009 May;15(5):620-6. doi: 10.1177/1352458508101950. Epub 2009 Mar 24. PMID: 19318511.
- 338: Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Lijoi F, Goretti B, Messina S, Picconi O, Tola MR, Trojano M. Subcutaneous Interferon Beta-1a Has

a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. *Ther Adv Neurol Disord*. 2009 Mar;2(2):67-77. doi: 10.1177/1756285608101379. PMID: 21180642; PMCID: PMC3002625.

339: Nicchia GP, Mastrototaro M, Rossi A, Pisani F, Tortorella C, Ruggieri M, Lia A, Trojano M, Frigeri A, Svelto M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. *Glia*. 2009 Oct;57(13):1363-73. doi: 10.1002/glia.20855. PMID: 19229993.

340: Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, Sessa E, La Volpe V, Russo P, Antonelli G. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres. *J Immunoassay Immunochem*. 2009;30(1):40-50. doi: 10.1080/15321810802569857. PMID: 19117201.

341: Trojano M, Paolicelli D, Fuiani A, Pellegrini F, Iaffaldano P, Drenzo V, D'Onghia M. Postmarketing evidence of disease-modifying drugs in multiple sclerosis. *Neurol Sci*. 2008 Sep;29 Suppl 2:S225-6. doi: 10.1007/s10072-008-0944-z. PMID: 18690499.

342: Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *Lancet Neurol*. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11. PMID: 18789766.

343: Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG; FEMIMS Group. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. *Mult Scler*. 2008 Nov;14(9):1225-33. doi: 10.1177/1352458508094882. Epub 2008 Aug 13. PMID: 18701568.

344: Italian REMS Study Group, Manconi M, Ferini-Strambi L, Filippi M, Bonanni E, Iudice A, Murri L, Gigli GL, Fratticci L, Merlino G, Terzano G, Granella F, Parrino L, Silvestri R, Aricò I, Dattola V, Russo G, Luongo C, Cicolin A, Tribolo A, Cavalla P, Savarese M, Trojano M, Ottaviano S, Cirignotta F, Simioni V, Salvi F, Mondino F, Perla F, Chinaglia G, Zuliani C, Cesnik E, Granieri E, Placidi F, Palmieri MG, Manni R, Terzaghi M, Bergamaschi R, Rocchi R, Ulivelli M, Bartalini S, Ferri R, Lo Fermo S, Ubiali E, Viscardi M, Rottoli M, Nobili L, Protti A, Ferrillo F, Allena M, Mancardi G, Guarnieri B, Londrillo F. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. *Sleep*. 2008 Jul;31(7):944-52. PMID: 18655317; PMCID: PMC2491510.

345: Ruggieri M, Pica C, Lia A, Zimatore GB, Modesto M, Di Liddo E, Specchio LM, Livrea P, Trojano M, Avolio C. Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic

cells in Multiple Sclerosis patients. *J Neuroimmunol.* 2008 Jul 15;197(2):140-6. doi: 10.1016/j.jneuroim.2008.04.032. Epub 2008 Jun 13. PMID: 18555539.

346: Ramunni A, De Robertis F, Brescia P, Saliani MT, Amoruso M, Prontera M, Dimonte E, Trojano M, Coratelli P. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis. *Ther Apher Dial.* 2008 Jun;12(3):250-4. doi: 10.1111/j.1744-9987.2008.00575.x. PMID: 18503704.

347: Cappellano G, Orilieri E, Comi C, Chiocchetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E, Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U. Variations of the perforin gene in patients with multiple sclerosis. *Genes Immun.* 2008 Jul;9(5):438-44. doi: 10.1038/gene.2008.35. Epub 2008 May 22. PMID: 18496551.

348: Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, Moiola L, Falautano M, De Caro MF, Lopez M, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M; Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features of childhood and juvenile MS. *Neurology.* 2008 May 13;70(20):1891-7. doi: 10.1212/01.wnl.0000312276.23177.fa. PMID: 18474844.

349: D'Alfonso S, Bolognesi E, Guerini FR, Barizzone N, Bocca S, Ferrante D, Castelli L, Bergamaschi L, Agliardi C, Ferrante P, Naldi P, Leone M, Caputo D, Ballerini C, Salvetti M, Galimberti D, Massacesi L, Trojano M, Momigliano-Richiardi P. A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. *Genes Immun.* 2008 Jan;9(1):7-15. doi: 10.1038/sj.gene.6364437. Epub 2007 Oct 11. PMID: 17928868.

350: Trojano M. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? *Neurology.* 2007 Oct 9;69(15):1478-9. doi: 10.1212/01.wnl.0000275545.08382.82. Erratum in: *Neurology.* 2008 Jan 29;70(5):408. PMID: 17923610.

351: Ruggieri M, Avolio C, Livrea P, Trojano M. Glatiramer acetate in multiple sclerosis: a review. *CNS Drug Rev.* 2007 Summer;13(2):178-91. doi: 10.1111/j.1527-3458.2007.00010.x. PMID: 17627671; PMCID: PMC6726353.

352: Solari A, Acquarone N, Pucci E, Martinelli V, Marrosu MG, Trojano M, Borreani C, Messmer Uccelli M. Communicating the diagnosis of multiple sclerosis a qualitative study. *Mult Scler.* 2007 Jul;13(6):763-9. doi: 10.1177/1352458506074689. Epub 2007 Mar 15. PMID: 17613605.

353: Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, Milanese C, Moiola L, Milani N, La Mantia L, Patti F, Pozzilli C, Trojano M, Comi G, Zaffaroni M; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group. Treatment of early-onset multiple sclerosis with intramuscular

- interferonbeta-1a: long-term results. *Neurol Sci.* 2007 Jun;28(3):127-32. doi: 10.1007/s10072-007-0804-2. Epub 2007 Jun 30. PMID: 17603763.
- 354: Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP. New natural history of interferon-beta-treated relapsing multiple sclerosis. *Ann Neurol.* 2007 Apr;61(4):300-6. doi: 10.1002/ana.21102. PMID: 17444502.
- 355: Patti F, Amato MP, Battaglia MA, Pitaro M, Russo P, Solaro C, Trojano M. Caregiver quality of life in multiple sclerosis: a multicentre Italian study. *Mult Scler.* 2007 Apr;13(3):412-9. doi: 10.1177/1352458506070707. Epub 2007 Jan 29. PMID: 17439911.
- 356: Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavalpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. *J Neurol.* 2007 May;254(5):597-604. doi: 10.1007/s00415-006-0332-7. Epub 2007 Apr 10. PMID: 17420930.
- 357: Giorelli M, Livrea P, Minervini MG, Trojano M. Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients. *Exp Neurol.* 2007 Apr;204(2):759-66. doi: 10.1016/j.expneurol.2007.01.013. Epub 2007 Jan 24. PMID: 17337267.
- 358: Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, Patti F, Vecchio R, Sorbi S, Trojano M. The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. *Mult Scler.* 2006 Dec;12(6):787-93. doi: 10.1177/1352458506070933. PMID: 17263008.
- 359: Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski JP. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. *Mult Scler.* 2006 Dec;12(6):769-74. doi: 10.1177/1352458506070775. PMID: 17263005.
- 360: Bergamaschi R, Quaglini S, Trojano M, Amato MP, Tavazzi E, Paolicelli D, Zipoli V, Romani A, Fuiani A, Portaccio E, Berzuini C, Montomoli C, Bastianello S, Cosi V. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. *J Neurol Neurosurg Psychiatry.* 2007 Jul;78(7):757-9. doi: 10.1136/jnnp.2006.107052. Epub 2007 Jan 12. PMID: 17220286; PMCID: PMC2117665.
- 361: Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, Rosati G, Savettieri G, Comi G, Livrea P; MSDN Study Group. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. *Mult Scler.* 2006 Oct;12(5):578-85. doi:

10.1177/1352458506070620. PMID: 17086903.

362: Trojano M, Paolicelli D, Lepore V, Fuiani A, Di Monte E, Pellegrini F, Russo P, Livrea P, Comi G; Italian MSDN Group. Italian Multiple Sclerosis Database Network. *Neurol Sci.* 2006 Sep;27 Suppl 5:S358-61. doi: 10.1007/s10072-006-0694-8. PMID: 16998720.

363: Games Collaborative Group, Ban M, Booth D, Heard R, Stewart G, Goris A, Vandebroek K, Dubois B, Laaksonen M, Ilonen J, Alizadeh M, Edan G, Babron MC, Brassat D, Clanet M, Cournu-Rebeix I, Fontaine B, Semana G, Goedde R, Epplen J, Weber A, Infante-Duarte C, Zipp F, Rajda C, Bencsik K, Vécsei L, Heggarty S, Graham C, Hawkins S, Liguori M, Momigliano-Richiardi P, Caputo D, Grimaldi LM, Leone M, Massacesi L, Milanese C, Salvetti M, Savettieri G, Trojano M, Bielecki B, Mycko MP, Selmaj K, Santos M, Maciel P, Pereira C, Silva A, Silva BM, Coraddu F, Marrosu MG, Akesson E, Hillert J, Datta P, Oturai A, Harbo HF, Spurkland A, Goertsches R, Villoslada P, Eraksoy M, Hensiek A, Compston A, Setakis E, Gray J, Yeo TW, Sawcer S. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. *J Neuroimmunol.* 2006 Oct;179(1-2):108-16. doi: 10.1016/j.jneuroim.2006.06.003. Epub 2006 Aug 24. Erratum in: *J Neuroimmunol.* 2007 Sep;189(1-2):175-6. multiple author names added. PMID: 16934875.

364: Amato MP, Zipoli V, Goretti B, Portaccio E, De Caro MF, Ricchiuti L, Siracusa G, Masini M, Sorbi S, Trojano M. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. *J Neurol.* 2006 Aug;253(8):1054-9. doi: 10.1007/s00415-006-0161-8. Epub 2006 Apr 11. PMID: 16609810.

365: Nocentini U, Pasqualetti P, Bonavita S, Buccafusca M, De Caro MF, Farina D, Girlanda P, Le Pira F, Lugaresi A, Quattrone A, Reggio A, Salemi G, Savettieri G, Tedeschi G, Trojano M, Valentino P, Caltagirone C. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. *Mult Scler.* 2006 Feb;12(1):77-87. doi: 10.1191/135248506ms1227oa. PMID: 16459723.

366: Trojano M, Paolicelli D, Zimatore GB, De Robertis F, Fuiani A, Di Monte E, Livrea P. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. *Neurol Sci.* 2005 Dec;26 Suppl 4:S179-82. doi: 10.1007/s10072-005-0511-9. PMID: 16388354.

367: Tortorella C, Bellacosa A, Paolicelli D, Fuiani A, Di Monte E, Simone IL, Giaquinto P, Livrea P, Trojano M. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. *J Neurol Sci.* 2005 Dec 15;239(1):95-9. doi: 10.1016/j.jns.2005.08.006. Epub 2005 Oct 4. PMID: 16209877.

368: Ruggieri M, Avolio C, Scacco S, Pica C, Lia A, Zimatore GB, Papa S, Livrea P, Trojano M. Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.

J Neurol. 2006 Feb;253(2):231-6. doi: 10.1007/s00415-005-0965-y. Epub 2005 Sep 30. PMID: 16184340.

369: Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. *Mult Scler*. 2005 Aug;11(4):441-6. doi: 10.1191/1352458505ms1193oa. PMID: 16042227.

370: Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, Milani N, Milanese C, Moiola L, Patti F, Pilato V, Pozzilli C, Trojano M, Zaffaroni M, Comi G; Immunomodulatory Treatment of Early onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. *Mult Scler*. 2005 Aug;11(4):420-4. doi: 10.1191/1352458505ms1206oa. PMID: 16042224.

371: Giorelli M, Livrea P, Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. *J Interferon Cytokine Res*. 2005 Jul;25(7):395-406. doi: 10.1089/jir.2005.25.395. PMID: 16022584.

372: Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, Mazarino MC, Giordano M, D'Alfonso S, Momigliano-Richiardi P, Liguori M, Zorzon M, Amoroso A, Trojano M, Monaco F, Leone M, Magnani C, Dianzani U. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. *J Neuroimmunol*. 2005 Jun;163(1-2):172-8. doi: 10.1016/j.jneuroim.2005.02.020. Epub 2005 Apr 25. PMID: 15885319.

373: Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Mitterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. *Neurology*. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8. PMID: 15824338.

374: Sisto D, Trojano M, Vetrugno M, Trabucco T, Iliceto G, Sborgia C. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. *Invest Ophthalmol Vis Sci*. 2005 Apr;46(4):1264-8. doi: 10.1167/iovs.03-1213. PMID: 15790888.

375: Ghezzi A, Ruggieri M, Trojano M, Filippi M; ITEMS Study Group. Italian studies on early-onset multiple sclerosis: the present and the future. *Neurol*

Sci. 2004 Nov;25 Suppl 4:S346-9. doi: 10.1007/s10072-004-0346-9. PMID: 15727231.

376: Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease? *Neurol Sci.* 2004 Nov;25 Suppl 4:S323-5. doi: 10.1007/s10072-004-0334-0. PMID: 15727226.

377: Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C; Evaluation of the EDMUS system (EVALUED) Study Group. European validation of a standardized clinical description of multiple sclerosis. *J Neurol.* 2004 Dec;251(12):1472-80. doi: 10.1007/s00415-004-0567-0. PMID: 15645346.

378: Trojano M. Can databasing optimise patient care? *J Neurol.* 2004 Sep;251 Suppl 5:v79-v82. doi: 10.1007/s00415-004-1513-x. PMID: 15549361.

379: Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, Farina D, Fazio MC, Girlanda P, Le Pira F, Liguori M, Lugaresi A, Nocentini U, Reggio A, Salemi G, Tedeschi G, Trojano M, Valentino P, Quattrone A. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. *J Neurol.* 2004 Oct;251(10):1208-14. doi: 10.1007/s00415-004-0508-y. PMID: 15503099.

380: Solaro C, Bricchetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, Gasperini C, Ghezzi A, Martinelli V, Milanese C, Patti F, Trojano M, Verdun E, Mancardi GL; PaIMS Study Group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. *Neurology.* 2004 Sep 14;63(5):919-21. doi: 10.1212/01.wnl.0000137047.85868.d6. PMID: 15365151.

381: Giorelli M, Livrea P, Trojano M. Post-receptorial mechanisms underlie functional dysregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. *J Neuroimmunol.* 2004 Oct;155(1-2):143-9. doi: 10.1016/j.jneuroim.2004.05.013. PMID: 15342205.

382: Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. *J Neurol Sci.* 2004 Aug 15;223(1):69-71. doi: 10.1016/j.jns.2004.04.023. PMID: 15261564.

383: Cosentino M, Zaffaroni M, Giorelli M, Marino F, Ferrari M, Bombelli R, Rasini E, Trojano M, Lecchini S, Livrea P, Comi G, Frigo G. Adrenergic mechanisms in multiple sclerosis: the neuro-immune connection? *Trends Pharmacol Sci.* 2004 Jul;25(7):350-1; author reply 351-2. doi: 10.1016/j.tips.2004.04.010. PMID: 15219975.

384: Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E,

- Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G; Italian Devic's Study Group (IDESG). Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. *J Neurol*. 2004 Jan;251(1):47-52. doi: 10.1007/s00415-004-0271-0. PMID: 14999489.
- 385: Liguori M, Cittadella R, Manna I, Valentino P, La Russa A, Serra P, Trojano M, Messina D, Ruscica F, Andreoli V, Romeo N, Livrea P, Quattrone A. Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. *J Neurol*. 2004 Feb;251(2):165-70. doi: 10.1007/s00415-004-0293-7. PMID: 14991350.
- 386: Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R, Lavolpe V, Vincent A, Comi G, Trojano M, Montalban X, Martino G. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. *Eur Cytokine Netw*. 2003 Jul-Sep;14(3):154-7. PMID: 14656689.
- 387: Trojano M, Paolicelli D, Bellacosa A, Cataldo S. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. *Neurol Sci*. 2003 Dec;24 Suppl 5:S268-70. doi: 10.1007/s10072-003-0171-6. PMID: 14652786.
- 388: Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuiani A, Livrea P; Southern Italy MS Group. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. *Mult Scler*. 2003 Oct;9(5):451-7. doi: 10.1191/1352458503ms948oa. PMID: 14582768.
- 389: Liguori M, Sawcer S, Setakis E, Compston A, Giordano M, D'Alfonso S, Mellai M, Malferrari G, Trojano M, Livrea P, De Robertis F, Massacesi L, Repice A, Ballerini C, Biagioli T, Bomprezzi R, Cannoni S, Ristori G, Salvetti M, Grimaldi LM, Biunno I, Comi G, Leone M, Ferro I, Naldi P, Milanese C, Gellera C, Loredana LM, Savettieri G, Salemi G, Aridon P, Caputo D, Rosa Guerini F, Ferrante P, Momigliano-Richiardi P. A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. *J Neuroimmunol*. 2003 Oct;143(1-2):97-100. doi: 10.1016/j.jneuroim.2003.08.020. PMID: 14575923.
- 390: Akesson E, Coraddu F, Marrosu MG, Massacesi L, Hensiek A, Harbo HF, Oturai A, Trojano M, Momigliano-Richiardi P, Cocco E, Murru R, Hillert J, Compston A, Sawcer S. Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. *J Neuroimmunol*. 2003 Oct;143(1-2):31-8. doi: 10.1016/j.jneuroim.2003.08.008. PMID: 14575911.
- 391: Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC, Girlanda P, Le Pira F, Liguori M, Logroscino G, Lugaresi A, Nocentini U, Reggio A, Salemi G, Serra P, Tedeschi G, Toma L, Trojano M, Valentino P, Quattrone A. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. *J Neurol*. 2003 Sep;250(9):1094-8. doi:

10.1007/s00415-003-0163-8. PMID: 14504972.

392: Avolio C, Giuliani F, Liuzzi GM, Ruggieri M, Paolicelli D, Riccio P, Livrea P, Trojano M. Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta. *Brain Res Bull.* 2003 Aug 15;61(3):357-64. doi: 10.1016/s0361-9230(03)00098-4. PMID: 12909305.

393: Gomez-Lira M, Liguori M, Magnani C, Bonamini D, Salviati A, Leone M, Andreoli V, Trojano M, Valentino P, Savettieri G, Quattrone A, Pignatti PF, Momigliano-Richiardi P, Giordano M. CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. *J Neuroimmunol.* 2003 Jul;140(1-2):216-21. doi: 10.1016/s0165-5728(03)00208-x. PMID: 12864992.

394: Alizadeh M, Babron MC, Birebent B, Matsuda F, Quelvennec E, Liblau R, Cournu-Rebeix I, Momigliano-Richiardi P, Sequeiros J, Yaouanq J, Genin E, Vasilescu A, Bougerie H, Trojano M, Martins Silva B, Maciel P, Clerget-Darpoux F, Clanet M, Edan G, Fontaine B, Semana G. Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. *Ann Neurol.* 2003 Jul;54(1):119-22. doi: 10.1002/ana.10617. PMID: 12838528.

395: Giorelli M, De Blasi A, Defazio G, Avolio C, Iacovelli L, Livrea P, Trojano M. Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. *Cell Commun Adhes.* 2002 Sep-Dec;9(5-6):259-72. doi: 10.1080/15419060216305. PMID: 12745437.

396: Reiber H, Thompson EJ, Grimsley G, Bernardi G, Adam P, Monteiro de Almeida S, Fredman P, Keir G, Lammers M, Liblau R, Menna-Barreto M, Sá MJ, Seres E, Sindic CJ, Teelken A, Trendelenburg C, Trojano M, van Antwerpen MP, Verbeek MM. Quality assurance for cerebrospinal fluid protein analysis: international consensus by an Internet-based group discussion. *Clin Chem Lab Med.* 2003 Mar;41(3):331-7. doi: 10.1515/CCLM.2003.053. PMID: 12705343.

397: Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. *J Neuroimmunol.* 2003 Mar;136(1-2):46-53. doi: 10.1016/s0165-5728(03)00006-7. PMID: 12620642.

398: Mellai M, Giordano M, D'Alfonso S, Marchini M, Scorza R, Danieli M.G., Leone M, Ferro I, Liguori M, Trojano M, Ballerini C, Massacesi L, Cannoni S, Bomprezzi R, Momigliano-Richiardi P. Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. *Hum Immunol.* 2003 Feb;64(2):274-84. doi: 10.1016/s0198-8859(02)00804-2. PMID: 12559630.

399: Liuzzi GM, Trojano M, Fanelli M, Avolio C, Fasano A, Livrea P, Riccio P.

Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. *Mult Scler.* 2002 May;8(3):222-8. doi: 10.1191/1352458502ms800oa. PMID: 12120694.

400: Giorelli M, Livrea P, Defazio G, Iacovelli L, Capobianco L, Picascia A, Sallese M, Martino D, Aniello MS, Trojano M, De Blasi A. Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes. *Cell Signal.* 2002 Aug;14(8):673-8. doi: 10.1016/s0898-6568(02)00011-6. PMID: 12020767.

401: Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M, Reggio A, Trojano M; Mu. S. I. C. Study Group. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. *J Neurol.* 2002 Feb;249(2):152-63. doi: 10.1007/pl00007858. PMID: 11985380.

402: Trojano M, Liguori M, Bosco Zimatore G, Bugarini R, Avolio C, Paolicelli D, Giuliani F, De Robertis F, Marrosu MG, Livrea P. Age-related disability in multiple sclerosis. *Ann Neurol.* 2002 Apr;51(4):475-80. doi: 10.1002/ana.10147. PMID: 11921053.

403: Trojano M, Paolicelli D. The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. *Neurol Sci.* 2001 Nov;22 Suppl 2:S98-102. doi: 10.1007/s100720100044. PMID: 11794488.

404: Giorelli M, Livrea P, Defazio G, Ricchiuti F, Pagano E, Trojano M. IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. *J Interferon Cytokine Res.* 2001 Oct;21(10):809-12. doi: 10.1089/107999001753238042. PMID: 11710992.

405: Broadley S, Sawcer S, D'Alfonso S, Hensiek A, Coraddu F, Gray J, Roxburgh R, Clayton D, Buttinelli C, Quattrone A, Trojano M, Massacesi L, Compston A. A genome screen for multiple sclerosis in Italian families. *Genes Immun.* 2001 Jun;2(4):205-10. doi: 10.1038/sj.gene.6363758. PMID: 11477475.

406: Avolio C, Ruggieri M, Cafforio P, Giuliani F, Silvestris F, Dammacco F, Livrea P, Trojano M. LFA-1 expression on CD4(+)CD45RO(+) peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a. *J Neurol Sci.* 2001 May 1;186(1-2):65-73. doi: 10.1016/s0022-510x(01)00506-8. PMID: 11412874.

407: Liguori M, Marrosu MG, Pugliatti M, Giuliani F, De Robertis F, Cocco E, Zimatore GB, Livrea P, Trojano M. Age at onset in multiple sclerosis. *Neurol Sci.* 2000;21(4 Suppl 2):S825-9. doi: 10.1007/s100720070020. PMID: 11205357.

408: Defazio G, Livrea P, Giorelli M, Martino D, Roselli F, Ricchiuti F, Trojano M. Interferon beta-1a downregulates TNFalpha-induced intercellular adhesion

molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. *Brain Res.* 2000 Oct 27;881(2):227-30. doi: 10.1016/s0006-8993(00)02814-6. PMID: 11036165.

409: Trojano M, Defazio G, Avolio C, Paolicelli D, Giuliani F, Giorelli M, Livrea P. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. *J Neurovirol.* 2000 May;6 Suppl 2:S47-51. PMID: 10871785.

410: D'Alfonso S, Nisticò L, Bocchio D, Bompreszi R, Marrosu MG, Murru MR, Lai M, Massacesi L, Ballerini C, Repice A, Salvetti M, Montesperelli C, Ristori G, Trojano M, Liguori M, Gambi D, Quattrone A, Tosi R, Momigliano-Richiardi P. An attempt of identifying MS-associated loci as a follow-up of a genomic linkage study in the Italian population. *J Neurovirol.* 2000 May;6 Suppl 2:S18-22. PMID: 10871779.

411: Defazio G, Nico B, Trojano M, Ribatti D, Giorelli M, Ricchiuti F, Martino D, Roncali L, Livrea P. Inhibition of protein kinase C counteracts TNFalpha-induced intercellular adhesion molecule 1 expression and fluid phase endocytosis on brain microvascular endothelial cells. *Brain Res.* 2000 Apr 28;863(1-2):245-8. doi: 10.1016/s0006-8993(00)02127-2. PMID: 10773213.

412: Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. *Neurology.* 1999 Oct 22;53(7):1402-8. doi: 10.1212/wnl.53.7.1402. PMID: 10534242.

413: D'Alfonso S, Nisticò L, Zavattari P, Marrosu MG, Murru R, Lai M, Massacesi L, Ballerini C, Gestri D, Salvetti M, Ristori G, Bompreszi R, Trojano M, Liguori M, Gambi D, Quattrone A, Fruci D, Cucca F, Richiardi PM, Tosi R. Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. *Eur J Hum Genet.* 1999 Apr;7(3):377-85. doi: 10.1038/sj.ejhg.5200301. PMID: 10234515.

414: Trojano M, Liguori M, De Robertis F, Stella A, Guanti G, Avolio C, Livrea P. Comparison of clinical and demographic features between affected pairs of Italian multiple sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. *J Neurol Sci.* 1999 Jan 15;162(2):194-200. doi: 10.1016/s0022-510x(98)00328-1. PMID: 10202987.

415: Trojano M, Avolio C, Ruggieri M, Defazio G, Giuliani F, Paolicelli D, Livrea P. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-1b treatment. *Mult Scler.* 1998 Jun;4(3):183-7. doi: 10.1177/135245859800400318. PMID: 9762671.

416: Defazio G, Trojano M, Ribatti D, Nico B, Giorelli M, De Salvia R, Russo G,

Roncali L, Livrea P. ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha. *J Neuroimmunol*. 1998 Aug 1;88(1-2):13-20. doi: 10.1016/s0165-5728(98)00064-2. PMID: 9688319.

417: Trojano M, Avolio C, Ruggieri M, De Robertis F, Giuliani F, Paolicelli D, Livrea P. Soluble intercellular adhesion molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. *Mult Scler*. 1998 Feb;4(1):39-44. doi: 10.1177/135245859800400110. PMID: 9532592.

418: Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calò A, Bernini ML, Gambi D, Prencipe M. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. *J Neurol*. 1997 Mar;244(3):153-9. doi: 10.1007/s004150050066. PMID: 9050955.

419: Simone IL, Federico F, Trojano M, Tortorella C, Liguori M, Giannini P, Picciola E, Natile G, Livrea P. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. *J Neurol Sci*. 1996 Dec;144(1-2):182-90. doi: 10.1016/s0022-510x(96)00224-9. PMID: 8994122.

420: Trojano M, Avolio C, Simone IL, Defazio G, Manzari C, De Robertis F, Calò A, Livrea P. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. *Neurology*. 1996 Dec;47(6):1535-41. doi: 10.1212/wnl.47.6.1535. PMID: 8960741.

421: Trojano M, Defazio G, Ricchiuti F, De Salvia R, Livrea P. Serum IgG to brain microvascular endothelial cells in multiple sclerosis. *J Neurol Sci*. 1996 Nov;143(1-2):107-13. doi: 10.1016/s0022-510x(96)00184-0. PMID: 8981306.

422: Trojano M, Avolio C, Manzari C, Calò A, De Robertis F, Serio G, Livrea P. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. *J Neurol Neurosurg Psychiatry*. 1995 Mar;58(3):300-6. doi: 10.1136/jnnp.58.3.300. PMID: 7897410; PMCID: PMC1073365.

423: Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, Gasperini C, Bozzao A, Gallucci M, Andreula C, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. *Can J Neurol Sci*. 1994 Aug;21(3):266-70. doi: 10.1017/s0317167100041263. PMID: 8000984.

424: Trojano M, Manzari C, Livrea P. Blood-brain barrier changes in multiple sclerosis. *Ital J Neurol Sci*. 1992 Dec;13(9 Suppl 14):55-64. PMID: 1345741.

- 425: Trojano M, Avolio C, De Robertis F, Manzari C, Rosato A, Livrea P. Utilità di un metodo standardizzato per la raccolta dei dati anamnestici nella sclerosi multipla (SM) [Usefulness of a standardized method for collecting anamnestic data in multiple sclerosis (MS)]. *Acta Neurol (Napoli)*. 1989 Apr-Jun;11(2-3):147-64. Italian. PMID: 2782115.
- 426: Trojano M, Logroscino GC, Picicchio L, Rosato A, Bordo B, Citterio A, Amato MP, Livrea P. The Multiple Sclerosis Cooperative Etiological Study in Italy: preliminary analysis of CSF findings. *Ital J Neurol Sci*. 1987 Jun;Suppl 6:71-6. PMID: 3654180.
- 427: Livrea P, Simone IL, Trojano M, Picicchio L, Logroscino G, Rosato A. Cerebrospinal fluid (CSF) parameters and clinical course of multiple sclerosis. *Riv Neurol*. 1987 May-Jun;57(3):189-96. PMID: 3672011.
- 428: Pozio G, Trizio M, Trojano M, Lochi L, Serlenga L. Miopatia distale sporadica ad esordio precoce. Descrizione di un caso [Sporadic distal myopathy with early onset. Description of a case]. *Acta Neurol (Napoli)*. 1986 Jun;8(3):304-9. Italian. PMID: 3739780.
- 429: Trojano M, Simone IL, Logroscino G, Picicchio L, Rosato A, Ragno T, Gaudiuso MR, Livrea P. Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. *J Neurol Sci*. 1986 May;73(3):325-38. doi: 10.1016/0022-510x(86)90157-7. PMID: 3014065.
- 430: Livrea P, Trojano M, Simone IL, Zimatore GB, Logroscino GC, Picicchio L, Lojacono G, Colella R, Ceci A. Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. *J Neurol*. 1985;231(6):336-9. doi: 10.1007/BF00313712. PMID: 3855968.
- 431: Livrea P, Trojano M, Simone IL, Zimatore GB, Picicchio L, Logroscino G, Cibelli G. Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. *J Neurol Sci*. 1984 Jun;64(3):245-58. doi: 10.1016/0022-510x(84)90173-4. PMID: 6206205.
- 432: Livrea P, Trojano M, Simone IL, Zimatore GB, Lamontanara G, Leante R. Intrathecal IgG synthesis in multiple sclerosis: comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG. *J Neurol*. 1981;224(3):159-69. doi: 10.1007/BF00313278. PMID: 6162012.
- 433: Livrea P, Zimatore GB, Simone IL, Trojano M, Lepore V, Ferrara V, Lupo FA, Pedone D. Isoelectric focusing and quantitative estimation of cerebrospinal fluid and serum IgG in idiopathic polyneuropathy. *J Neurol*. 1980;223(1):1-12. doi: 10.1007/BF00313135. PMID: 6155449.

434: Livrea P, Zimatore GB, Simone IL, Lepore V, Trojano M, Loreto M, De Blasi A, Gennarini GF. Isoelectric focusing and crossed immunoelectrofocusing of cerebrospinal fluid proteins in neurological disorders. *Acta Neurol (Napoli)*. 1978 Dec;33(6):501-17. PMID: 754527.